



UNIVERSITI PUTRA MALAYSIA

***SYNTHESIS, CHARACTERIZATION AND CYTOTOXICITY EVALUATION OF
CARBOXYLATED CARBON NANOTUBES FUNCTIONALIZED WITH
SILIBININ, BETULINIC ACID AND LEVODOPA FOR DRUG DELIVERY***

JULIA TAN MEIHUA

ITMA 2015 6



**SYNTHESIS, CHARACTERIZATION AND CYTOTOXICITY EVALUATION
OF CARBOXYLATED CARBON NANOTUBES FUNCTIONALIZED WITH
SILIBININ, BETULINIC ACID AND LEVODOPA FOR DRUG DELIVERY**

By

JULIA TAN MEIHUA

Thesis Submitted to the School of Graduate Studies,
Universiti Putra Malaysia, in Fulfilment of the Requirements
for the Degree of Doctor of Philosophy

August 2015

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of
the requirement for the degree of Doctor of Philosophy

**SYNTHESIS, CHARACTERIZATION AND CYTOTOXICITY EVALUATION
OF CARBOXYLATED CARBON NANOTUBES FUNCTIONALIZED WITH
SILIBININ, BETULINIC ACID AND LEVODOPA FOR DRUG DELIVERY**

By

JULIA TAN MEIHUA

August 2015

Chairman: Professor Mohd Zobir bin Hussein, PhD
Faculty: Institute of Advanced Technology

Current methods of conventional drugs administered via liquids or tablets are often faced with problems like inefficient biodistribution, low solubility, poor bioavailability, long term toxicity and limited drug efficacy. As a result, many efforts have been carried out in the past to overcome the above mentioned limitations. This has led to the development of nanomaterial-based carrier as novel drug delivery system. In this study, commercially available carboxylated carbon nanotubes (CNTs) were used as the nano drug carrier due to their attractive physico-chemical properties which facilitate functionalization of therapeutic molecules onto their external walls or being encapsulated inside the nanotubes. Therefore, the main objective of the present work was to develop drug delivery formulation for silibinin (SB), betulinic acid (BA) and levodopa (LD) with carboxylated single walled (SWCNTs-COOH) and multiwalled carbon nanotubes (MWCNTs-COOH) separately for enhanced delivery efficiency into targeted cells with sustained-release effect.

The resulting five nanohybrids, namely SWCNTs-SB, MWCNTs-SB, SWCNTs-BA, MWCNTs-BA and SWCNTs-LD, were prepared by non-covalent method via π - π and hydrogen bonds as well as hydrophobic interactions without the use of any cross-linker agent. The physico-chemical properties of the resulting nanohybrids, *i.e.* chemical interaction, elemental composition, crystallinity, thermal property, surface morphology, drug loading capacity and drug releasing characteristic were studied using Fourier transform infrared (FTIR) and Raman spectroscopies, elemental analysis (CHN-S), powder X-ray diffractometry (PXRD), thermogravimetric analysis (TGA), transmission electron microscopy (TEM), field emission scanning electron microscopy (FESEM) and ultraviolet-visible spectrophotometry (UV-Vis). In order to assess the cytotoxicity characteristic of the synthesized nanohybrids, human cancer cell lines HepG2 (human liver hepatocellular carcinoma cell lines) and A549 (human lung adenocarcinoma epithelial cell lines) were used in comparison to normal cell lines MRC-5 (human lung cell lines), 3T3 (mouse fibroblast cell lines) and PC12 (rat neuronal cell lines).

The loading of drug in SWCNTs-SB, MWCNTs-SB, SWCNTs-BA, MWCNTs-BA and SWCNTs-LD nanohybrids was estimated to be around 46.0, 35.1, 20.0, 14.8 and 38.2 w/w%, respectively as determined by UV-Vis, and these values have been verified by TGA. Both FTIR and Raman spectroscopy studies confirmed that the conjugation process has taken place between drugs and the nanocarriers. The PXRD results showed that tubular structures of the nanocarriers were not affected by drug loading mechanism. Drug release profiles have been investigated at different pH values, showing the influence of pH on the drug release process. In addition, the synthesized nanohybrids possessed favourable sustained-release property to be used in a controlled-release formulation, with satisfactory coefficients conformed well to the *pseudo*-second order release kinetic model.

Preliminary *in vitro* cytotoxicity studies suggest that the drug-loaded nanohybrids (*i.e.* SWCNTs-SB, MWCNTs-SB, SWCNTs-BA and MWCNTs-BA) are not acutely toxic while significantly inhibiting the growth of cancer cells in comparison with pure drugs after 72 hours of treatment using MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] assay. Cell viability assay was also performed in PC12 cell lines, a widely used *in vitro* Parkinson's model for neurotoxicity study, in order to investigate their potential effects on normal neuronal cells. It was found that the synthesized SWCNTs-LD did not compromise the cell viability of PC12 cells but remain stable throughout the experiment.

With the addition of the surface coating agents, the initial burst of drugs was dramatically improved and thus, resulted in a more prolonged and sustained release fashion. In general, the coated nanohybrids exhibit a *pseudo*-second-order release kinetics which was driven by the ion exchange process between the ionized nanohybrids and the anions in the release medium. On top of that, it was noted that the surfactant and polymer coating improved the biocompatibility of the drug-loaded nanohybrids significantly in comparison to the uncoated ones.

In conclusion, the findings from this work indicate that the carboxylated CNTs with the desired properties could be developed as an efficient drug nanocarrier to non-covalently conjugate poorly water-soluble drug for effective drug delivery in cancer chemotherapies and the treatment of neurodegenerative diseases.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**SINTESIS, PENCIRIAN DAN PENILAIAN KESITOTOKSIKAN NANOTIUB
KARBON TERKARBOKSILAT DENGAN FUNGSIAN SILIBININ, ASID
BETULINIK DAN LEVODOPA UNTUK PENYAMPAIAN UBAT**

Oleh

JULIA TAN MEIHUA

Ogos 2015

Pengerusi: Profesor Mohd Zobir bin Hussein, PhD
Fakulti: Institut Teknologi Maju

Kaedah semasa pengurusan ubat konvensional yang diberikan melalui cecair atau pil sering berhadapan dengan masalah seperti bioserakan yang kurang cekap, kelarutan yang rendah, bioketersediaan yang rendah, ketosikan jangka panjang dan kerbekesanan ubat yang terhad. Akibatnya, banyak usaha telah dilakukan pada masa lalu untuk mengatasi kekurangan yang dinyatakan di atas. Ini telah membawa kepada pembangunan pembawa ubatan berdasarkan bahan nano sebagai sistem penyampaian ubat baru. Dalam kajian ini, nanotiub karbon terkarboksilat (CNTs) yang diperolehi secara komersial telah digunakan sebagai pembawa ubat nano, disebabkan oleh sifat fizik-kimia mereka yang menarik, memudahkan pemfungsian molekul terapeutik ke atas dinding luar atau terkapsul di dalam nanotiub. Justeru itu, objektif utama kajian ini adalah untuk merumuskan formulasi penyampaian ubat untuk silibinin (SB), asid betulinik (BA) dan levodopa (LD) dengan nanotiub karbon berdinding tunggal terkarboksilat (SWCNTs-COOH) dan berdinding pelbagai (MWCNTs-COOH) secara berasingan untuk mempertingkatkan kecekapan penghantaran ubat ke dalam sel-sel sasaran dengan kesan pembebasan yang berterusan.

Sebanyak lima jenis hibrid nano, iaitu SWCNTs-SB, MWCNTs-SB, SWCNTs-BA, MWCNTs-BA dan SWCNTs-LD telah disediakan dengan kaedah bukan kovalen melalui interaksi ikatan π - π , hidrogen dan hidrofobik tanpa menggunakan sebarang ejen rangkaian silang. Sifat-sifat fizik-kimia hibrid nano yang dihasilkan, iaitu interaksi kimia, komposisi keunsuran, kehabluran, sifat terma, morfologi permukaan, keupayaan muatan ubat dan ciri pembebasan ubat telah dikaji dengan spektroskopi inframerah transformasi Fourier (FTIR) dan Raman, analisis unsur (CHN-S), kajian pembelauan sinar-X (PXRD), analisis termogravimetri (TGA), mikroskopi elektron pancaran (TEM), mikroskopi elektron imbasan (FESEM) dan spektrofotometri ultraungu-nampak (UV-Vis). Sebagai usaha untuk menilai ciri kesitotoksikan hibrid nano yang disintesikan, titisan sel kanser manusia HepG2 (titisan sel karsinoma hepatoselular hati manusia) dan A549 (titisan sel epitelium adenokarsinoma paru-paru manusia) telah digunakan sebagai perbandingan kepada titisan sel normal MRC-5 (titisan sel paru-paru manusia), 3T3 (titisan sel fibroblas tikus) dan PC12 (titisan sel neuronal tikus).

Kandungan ubat dalam hibrid nano SWCNTs-SB, MWCNTs-SB, SWCNTs-BA, MWCNTs-BA dan SWCNTs-LD masing-masing adalah dianggarkan di sekitar 46.0, 35.1, 20.0, 14.8 dan 38.2 w/w% seperti mana yang ditentukan dengan kaedah UV-Vis, dan nilai-nilai ini telah disahkan oleh TGA. Kedua-dua kajian spektroskopi FTIR dan Raman mengesahkan bahawa proses konjugasi telah berlaku di antara ubat dan pembawa nano. Keputusan PXRD menunjukkan bahawa struktur pembawa nano berbentuk tiub tidak dipengaruhi oleh mekanisma muatan ubat. Profil pembebasan ubat telah disiasat pada nilai-nilai pH yang berbeza, menunjukkan pH mempunyai pengaruh ke atas proses pembebasan ubat. Di samping itu, hibrid nano yang disintesikan mempunyai sifat pembebasan berterusan yang sesuai untuk digunakan dalam formulasi pembebasan terkawal, dengan pekali-pekali memuaskan yang mematuhi model kinetik pembebasan *pseudo*-kedua.

Kajian kesitoloksikan *in vitro* awal mencadangkan bahawa hibrid nano muatan ubat (iaitu SWCNTs-SB, MWCNTs-SB, SWCNTs-BA dan MWCNTs-BA) adalah tidak toksik secara akut sementara menghalang pertumbuhan sel-sel kanser nyata sekali berbanding dengan ubat tulen selepas 72 jam rawatan menggunakan assai MTT [3-(4,5-dimetilthiazolil-2)-2,5-difeniltetrazolium bromida]. Assai kebolehhidupan sel juga dilakukan pada sel PC12, satu model Parkinson *in vitro* yang digunakan secara meluas untuk kajian neurotoksisiti, sebagai usaha untuk menyiasat kesan potensi mereka pada sel-sel neuronal yang normal. Didapati bahawa SWCNTs-LD yang disintesikan tidak menjaskan kebolehhidupan sel-sel PC12, tetapi kekal stabil sepanjang eksperimen.

Dengan penambahan ejen salutan permukaan, kesan awal pecahan ubat telah dipertingkatkan secara dramatik dan justeru itu, mengakibatkan pelepasan yang lebih berpanjangan dan berterusan. Secara umumnya, hibrid nano tersalut mempamerkan kinetik pelepasan *pseudo*-kedua yang disebabkan oleh proses pertukaran ion antara hibrid nano terion dan anion dalam medium pelepasan. Selain itu, didapati bahawa salutan surfaktan dan polimer meningkatkan biokompatibiliti ubat-muatan hibrid nano dengan ketara berbanding dengan sampel yang tidak bersalut.

Kesimpulannya, hasil dari kajian ini menunjukkan bahawa CNTs terkarboksilat dengan ciri-ciri yang diingini boleh dibangunkan sebagai pembawa ubat nano yang berkesan untuk aplikasi penyampaian ubat dalam kemoterapi kanser dan rawatan penyakit neurodegeneratif.

ACKNOWLEDGEMENTS

First and foremost, I give thanks and praises to The Almighty God for His showers of blessings and guidance to complete this thesis successfully with a sense of satisfaction.

I wish to offer my sincerest gratitude to my committee chair, Professor Dr. Mohd Zobir Hussein, who has supported me throughout my research work with his excellent guidance, valuable suggestions, and immense knowledge while allowing me the room to work in my own way. I attribute the level of my PhD degree to his encouragement and effort and without him, this thesis would not have been completed in a timely manner.

My deepest appreciation is also directed to the rest of my committee members, Associate Professor Datin Dr. Sharida Fakurazi and Professor Dr. Hairuszah Ithnin for their kind assistance, positive encouragement and insightful comments during the course of this study. My heartfelt thanks also go to Dr. Palanisamy Arulselvan, Dr. How Chee Wun, and Dr. Samer Hasan Ahmad Hussein-Al-Ali for their unselfish sharing of knowledge and enlightening me the first glance of my research work.

In addition, I thank the Universiti Putra Malaysia for providing the support and facility that I needed to produce and complete this doctoral thesis. I am also indebted to the Ministry of Science, Technology and Innovation (MOSTI) and MyBrain15 for funding my PhD study.

My thanks to the entire staff and fellow lab mates in the Laboratory of Materials Synthesis and Characterization (MSCL) and the Laboratory of Vaccines and Immunotherapeutics (LIVES) for providing equipment and technical assistance directly or indirectly for the past few years, particularly Mrs. Sarinawani Abdul Ghani, Mrs. Rosnah Nawang, Mrs. Roslina Abdul Rashid, Mrs. Noor Lina Shamsuddin, Mr. Mohd Kadri Masaud, Mrs. Tumirah Khadiran, Mrs. Ruzanna, Dr. Farah Barahuie, Dr. Dena Dorniani, Dr. Saifullah Bullo, Dr. Aminu Umar Kura, Mr. Govindarajan Karthivashan and Dr. Foo Jhi Biau, for the stimulating discussions and for all the fun we have had in the last four years.

I wish to thank my beloved parents and my siblings for their enduring love and supporting me spiritually throughout the years of my study at University. My heartfelt thanks and unreserved love goes to my husband Kwan Yong Khang and my adorable kids Kwan Yu Xuan and Kwan Yu Han. They are the source of my inspiration and motivation. My special thanks and appreciations are also extended to my late father-in-law and mother-in-law for their kind understanding and unconditional love towards taking care of my children while allowing me the space to focus on my research work.

Last but not least, I would like to thank all those who had contributed in many ways to the successful realization of this thesis, as well as expressing my apology that I could not mention personally one by one.

I certify that a Thesis Examination Committee has met on 6 August 2015 to conduct the final examination of Julia Tan Meihua on her thesis entitled “Synthesis, Characterization and Cytotoxicity Evaluation of Carboxylated Carbon Nanotubes Functionalized with Silibinin, Betulinic Acid and Levodopa for Drug Delivery” in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the degree of Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

Khamirul Amin Matori, PhD

Associate Professor

Institute of Advanced Technology

Universiti Putra Malaysia

(Chairman)

Mansor Hashim, PhD

Associate Professor

Institute of Advanced Technology

Universiti Putra Malaysia

(Internal Examiner)

Mohamed Ibrahim Mohamed Tahir, PhD

Senior Lecturer

Faculty of Science

Universiti Putra Malaysia

(Internal Examiner)

Ahmed Kamal, PhD

Professor

CSIR-Indian Institute of Chemical Technology

India

(External Examiner)

ZULKARNAIN ZAINAL, PhD

Professor and Deputy Dean

School of Graduate Studies

Universiti Putra Malaysia

Date: 22 September 2015

The thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Mohd Zobir bin Hussein, PhD

Professor

Institute of Advanced Technology

Universiti Putra Malaysia

(Chairman)

Sharida Fakurazi, PhD

Associate Professor Datin

Institute of Bioscience

Universiti Putra Malaysia

(Internal Member)

Hairuszah Ithnin, PhD

Professor

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Internal Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean

School of Graduate Studies

Universiti Putra Malaysia

Date:

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature : _____ Date: _____

Name and Matric No.: Julia Tan Meihua (GS28697)

Declaration by members of supervisory committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: _____

Name of
Chairman of
Supervisory Committee: Prof. Dr.
Mohd Zobir Hussein

Signature: _____

Name of
Member of
Supervisory Committee: Assoc. Prof. Datin
Dr.Sharida Fakurazi

Signature: _____

Name of
Member of
Supervisory Committee: Prof. Dr.
Hairuszah Ithnin

TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	iii
ACKNOWLEDGEMENTS	v
APPROVAL	vi
DECLARATION	viii
LIST OF TABLES	xv
LIST OF FIGURES	xvii
LIST OF APPENDICES	xxiii
LIST OF ABBREVIATIONS	xxiv
 CHAPTER	
1 INTRODUCTION	1
1.1 Background of Study	1
1.2 Problem Statement	1
1.3 Scope of Study	4
1.4 Hypotheses	4
1.5 Objectives	4
2 LITERATURE REVIEW	5
Part I: The Evolutionary Development in Drug Discovery and Delivery	5
2.1 Drug Discovery in the Past	5
2.2 Drug Delivery in the Present	6
2.2.1 Oral Drug Delivery	7
2.2.2 Parental Drug Delivery	8
2.2.3 Transdermal Drug Delivery	12
2.2.4 Transmucosal Drug Delivery	14
2.2.5 Pulmonary Drug Delivery	20
2.3 Drug Delivery in the Future	22
2.3.1 The Challenges Faced by Drug Delivery Industries	22
2.4 Summary	24
2.5 Copyright Permission	24
Part II: A Review on Characterizations and Biocompatibility of Functionalized Carbon Nanotubes in Drug Delivery Designs	25
2.6 Introduction	25
2.7 Functionalization of Carbon Nanotubes	27
2.7.1 Covalent Functionalization	27
2.7.2 Non-Covalent Functionalization	28
2.8 Design of Carbon Nanotube-Mediated Delivery Systems in Therapeutics	34
2.8.1 Determination of Parameters in a Delivery Mechanism	34
2.8.2 Determination of Characterization Methods	36
2.9 Reviews on Bioassays using Functionalized Carbon Nanotubes	43
2.9.1 <i>In Vitro</i> Biocompatibility Assays	44
2.10 Summary	50
2.11 Copyright Permission	51

3 MATERIALS AND METHODS	52
3.1 Materials	52
3.2 Optimization of Drug Solubility in Different Solvents	53
3.2.1 Silibinin Solubility Test in Different Solvents	53
3.2.2 Betulinic Acid Solubility Test in Different Solvents	59
3.2.3 Levodopa Solubility Test in Different Solvents	63
3.3 Preparation of Nanohybrids	68
3.3.1 Preparation of SWCNTs-Silibinin	68
3.3.2 Preparation of MWCNTs-Silibinin	68
3.3.3 Preparation of SWCNTs-Betulinic Acid	69
3.3.4 Preparation of MWCNTs-Betulinic Acid	69
3.3.5 Preparation of SWCNTs-Levodopa	69
3.4 Preparation of Biopolymer-Coated Carboxylated CNTs Nano hybrids	70
3.5 Physico-Chemical Analysis and Characterizations	70
3.5.1 Fourier Transform Infrared Spectroscopy	70
3.5.2 Raman Spectroscopy	70
3.5.3 Elemental Analyzer	71
3.5.4 Powder X-Ray Diffractometry	71
3.5.5 Thermal Property	71
3.5.6 Transmission Electron Microscopy	71
3.5.7 Field Emission Scanning Electron Microscopy	71
3.5.8 UV-Visible Spectrophotometry	72
3.5.9 <i>In Vitro</i> Drug Release Profile	72
3.6 Cell Lines and Culture Conditions	73
3.6.1 Preparation of Nanohybrids for Cytotoxicity Assay	73
3.6.2 Statistical Analysis	75
3.7 Contribution of Authors	75
4 IN VITRO NANODELIVERY OF SILIBININ AS AN ANTICANCER DRUG UNDER PH RESPONSE	76
4.1 Introduction	76
4.2 Experimental	77
4.2.1 Materials and Reagents	77
4.2.2 Sample Characterization	77
4.2.3 Evaluation of Silibinin Solubility	78
4.2.4 Synthesis of SWCNTs-Silibinin Nano hybrid	78
4.2.5 Loading Capacity of CNTs with Silibinin	78
4.2.6 Controlled-Release Study	80
4.2.7 Cell Culture	80
4.2.8 Cell Cytotoxicity Assay	80
4.3 Results and Discussion	80
4.3.1 FTIR Spectroscopy	80
4.3.2 Raman Spectroscopy	81
4.3.3 Surface Properties	82
4.3.4 Release Behavior of Silibinin from Its CNTs Nanocarrier	83
4.3.5 Release Kinetics of Silibinin from Its CNTs Nanocarrier	84
4.3.6 Cytotoxicity Effects of Silibinin, Silibinin-Loaded Nano hybrid and SWCNTs-COOH	87
4.4 Summary	88
4.5 Copyright Permission	89

5	CHARACTERIZATION AND <i>IN VITRO</i> SUSTAINED RELEASE OF SILIBININ FROM PH RESPONSIVE CARBON NANOTUBE-BASED DRUG DELIVERY SYSTEM	90
5.1	Introduction	90
5.2	Materials and Methods	92
5.2.1	Conjugation of MWCNTs with Silibinin	92
5.2.2	Physico-Chemical Characterization of MWCNTs-Silibinin	93
5.2.3	<i>In Vitro</i> Drug Release Studies	94
5.2.4	Cell Lines and Culture Conditions	94
5.2.5	Determination of Cytotoxicity (MTT Assay)	94
5.2.6	Statistical Analysis	94
5.3	Results and Discussions	95
5.3.1	Fourier Transform Infrared Spectroscopy	95
5.3.2	Raman Scattering Studies	96
5.3.3	Thermogravimetric Analysis	97
5.3.4	Surface Morphology	98
5.3.5	<i>In Vitro</i> Drug Release Study	99
5.3.6	<i>In Vitro</i> Anticancer Effect of MWCNTs-Silibinin	102
5.4	Summary	103
5.5	Copyright Permission	103
6	SUSTAINED RELEASE AND CYTOTOXICITY EVALUATION OF CARBON NANOTUBE-MEDIATED DRUG DELIVERY SYSTEM FOR BETULINIC ACID	104
6.1	Introduction	104
6.2	Materials and Methods	106
6.2.1	Materials and Characterizations	106
6.2.2	Calibration Curve	106
6.2.3	Preparation of SWCNTs-Betulinic Acid Conjugate	107
6.2.4	Assessment of SWCNTs-COOH Loading with Betulinic Acid	107
6.2.5	Measurement of Betulinic Acid Controlled-Release <i>In Vitro</i>	108
6.2.6	Cell Lines and Cell Viability Tests	108
6.3	Results and Discussions	109
6.3.1	Characterization of SWCNTs-Betulinic Acid Conjugate	109
6.3.2	Loading, Release, and Kinetic Behaviour of Betulinic Acid	114
6.3.3	Cytotoxicity Evaluation	118
6.4	Summary	120
6.5	Copyright Permission	121
7	CHARACTERIZATION AND <i>IN VITRO</i> STUDIES OF ANTICANCER EFFECT OF OXIDIZED CARBON NANOTUBES FUNCTIONALIZED WITH BETULINIC ACID	122
7.1	Introduction	122
7.2	Materials and Methods	124
7.2.1	Chemicals	124
7.2.2	Physico-Chemical Characterization	124
7.2.3	Preparation of CNTs-Betulinic Acid Formulation	124
7.2.4	Drug Loading Evaluation	125
7.2.5	<i>In Vitro</i> Release of Drug at Different pH Levels	125
7.2.6	Cell Cultures: 3T3, HepG2, and A549 Cell Lines	125

7.2.7	Preparation of CNTs-Betulinic Acid Formulation for Cell Viability Assay	125
7.2.8	Cytotoxicity Assay	126
7.2.9	Statistics	126
7.3	Results and Discussions	127
7.3.1	Physico-Chemical Characterization	127
7.3.2	<i>In Vitro</i> Release Behavior of Drug at Different pH Levels	133
7.3.3	<i>In Vitro</i> Release Kinetics of Drugs at Different pH Levels	135
7.3.4	Cytotoxicity Assay	137
7.4	Summary	139
7.5	Copyright Permission	139
8	RELEASE BEHAVIOUR AND TOXICITY EVALUATION OF LEVODOPA FROM CARBOXYLATED SINGLE-WALLED CARBON NANOTUBES	
		140
8.1	Introduction	140
8.2	Experimental	142
8.2.1	Materials	142
8.2.2	Preparation of Standard Solutions	142
8.2.3	Synthesis of SWCNTs-Levodopa Nanohybrid	143
8.2.4	<i>In Vitro</i> Drug Release Response	144
8.2.5	Characterization	145
8.2.6	PC12 Cell Lines	145
8.3	Results and Discussion	146
8.3.1	Characterization of SWCNTs-Levodopa Nanohybrid	146
8.3.2	Release Behaviour of Levodopa	150
8.3.3	Release Kinetics of Levodopa	151
8.4	Summary	155
8.5	Copyright Permission	155
9	IN VITRO RELEASE CHARACTERISTICS AND CYTOTOXIC EFFECTS OF SILIBININ-LOADED SINGLE WALLED CARBON NANOTUBES USING BIOPOLYMERS AS SURFACTANTS	
		156
9.1	Introduction	156
9.2	Materials and Methods	158
9.2.1	Chemicals	158
9.2.2	Instruments	158
9.2.3	Preparation of Carbon Nanotubes-Silibinin Formulation (SWCNTs-SB)	158
9.2.4	Preparation of the Surfactant-Coated SWCNTs-SB Nanocomposites	159
9.2.5	Drug Loading and Releasing	159
9.2.6	Cell Culture Conditions	159
9.2.7	MTT Cytotoxicity Assay	160
9.3	Results and Discussions	160
9.3.1	Fourier Transform Infrared	160
9.3.2	Raman	163
9.3.3	Field Emission Scanning Electron Microscope (FESEM)	165
9.3.4	Drug Release Behaviour at pH 7.4	167
9.3.5	Drug Release Kinetics and Possible Mechanisms	168
9.3.6	Effects of Surfactant-Coated SWCNTs-SB on Cell Viability	171

9.4 Summary	172
9.5 Letter of Submission	173
10 BIOMATERIALS FOR DRUG DELIVERY	
10.1 Introduction	174
10.2 Experimental Section	174
10.2.1 Chemicals	176
10.2.2 Characterization	176
10.2.3 Synthesis of Betulinic Acid-Loaded Single Walled Carbon Nanotubes	176
10.2.4 Synthesis of Biopolymer-Coated SWCNTs-BA Nanocomposites	177
10.2.5 Drug Release and Kinetic Studies of Biopolymer-Coated SWCNTs- BA Nanocomposites	178
10.2.6 Cell Line and Cell Culture	178
10.2.7 Cytotoxicity assay	179
10.3 Results and Discussion	179
10.3.1 Chemical Structures of the Biopolymer-Coated SWCNTs-BA Nanocomposites	179
10.3.2 Morphological Studies of the SWCNTs-BA Nanocomposites	184
10.3.3 Drug Release and Kinetic Studies of the Biopolymer-Coated SWCNTs-BA Nanocomposites	187
10.3.4 Cytotoxicity Assay	190
10.4 Summary	192
10.5 Letter of Submission	193
11 CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE RESEARCH	194
11.1 Conclusions	194
11.2 Future Works	198
REFERENCES	199
APPENDICES	236
BIODATA OF STUDENT	244
LIST OF PUBLICATIONS	245

LIST OF TABLES

Table		Page
2.1	Evolution of osmotic pumps throughout the history of oral osmotically drug delivery systems	8
2.2	Classification of biodegradable injectable <i>in situ</i> forming drug delivery systems according to their mechanisms of depot formation	9
2.3	Structural features of different sections of nasal cavity and their relative impact on permeability	17
2.4	Summary of colon-specific drug delivery strategies	19
2.5	Some of the recent development of CNTs for <i>in vitro</i> drug delivery applications	29
2.6	The characteristic features of SWCNTs characterized by Raman spectroscopy	38
3.1	The properties of the commercial CNTs provided by the manufacturer	52
4.1	Correlation coefficient (R^2) and rate constants (k) obtained by fitting the silibinin release data for the SWCNTs-COOH in PBS solutions at pH 7.4 and pH 4.8	85
5.1	Correlation coefficient (R^2) and rate constants (k) obtained by fitting the silibinin release data for the MWCNTs-COOH in PBS solutions at pH 7.4 and pH 4.8	100
6.1	Correlation coefficient, rate constant, and half-life obtained by fitting the data for release of betulinic acid from SWCNTs-BA into PBS solutions at pH 7.4 and 4.8	116
7.1	Correlation coefficient, rate constant, and half-time obtained by fitting the data of the release of betulinic acid from oxidized MWCNTs into PBS solutions at pH 7.4 and 4.8 using <i>pseudo-first</i> , <i>pseudo-second</i> , and parabolic diffusion kinetic models	135
8.1	Results of the CHN-S elemental analysis of the SWCNTs-COOH, levodopa and SWCNTs-LD nanohybrid	147
8.2	Location and relative intensity of the Raman peaks of SWCNTs-COOH and SWCNTs-LD nanohybrid	148

8.3	Correlation coefficient, rate constant and half-time obtained by fitting the data of the release of levodopa from SWCNTs-COOH into pH 7.4 and pH 4.8 PBS solutions at 25°C	151
9.1	Peak positions of D and G-bands as well as I_D/I_G ratios for SWCNTs-COOH, SWCNTs-SB and the surfactant-coated nanocomposites	165
9.2	Linear regression analysis obtained by fitting the silibinin release data from biocompatible surfactant-coated SWCNTs-SB nanocomposites into PBS solution at pH 7.4	169
10.1	TGA data of the coated samples without the anticancer drug, betulinic acid	178
10.2	Raman shifts for SWCNTs-COOH, SWCNTs-BA and the biopolymer-coated SWCNTs-BA nanocomposites	184
10.3	The correlation coefficients (R^2) obtained by fitting the betulinic acid release data from biocompatible polymer-coated SWCNTs-BA nanocomposites into PBS solution at pH 7.4	189

LIST OF FIGURES

Figure		Page
1.1	Chemical structure of silibinin.	2
1.2	Molecular structure of betulinic acid.	2
1.3	Structure of levodopa.	3
2.1	Schematic representation of drug delivery using different designs of microneedles.	14
2.2	The structure of the oral mucosa.	16
2.3	The pulmonary route of delivery.	20
2.4	CNTs: SWCNTs on the left; and MWCNTs on the right.	26
2.5	FTIR spectra of (A) as-received SWCNTs; (B) SWCNTs functionalized with carboxylic acid; (C) DOX; (D) DOX-loaded SWCNTs, and (E) DOX-loaded SWCNTs encapsulated with CHI-FA.	37
2.6	Applications of <i>f</i> -CNTs in nanomedicine.	44
3.1	UV-Vis spectrum of silibinin using DMSO as solvent.	53
3.2	Plot of absorbance against concentration of silibinin using DMSO as solvent.	54
3.3	Calibration curve of absorbance against concentration for silibinin at 290 nm using DMSO as solvent.	55
3.4	UV-Vis spectrum of silibinin using ethanol as solvent.	56
3.5	Plot of absorbance against concentration of silibinin using ethanol as solvent.	57
3.6	Calibration curve of absorbance against concentration for silibinin at 288 nm using ethanol as solvent.	58
3.7	UV-Vis absorption spectrum of betulinic acid using DMSO as solvent.	59
3.8	UV-Vis absorption spectrum of betulinic acid using methanol as solvent.	60

3.9	Plot of absorbance against concentration of betulinic acid using methanol as solvent.	61
3.10	Calibration curve of absorbance against concentration for betulinic acid at 210 nm using methanol as solvent.	62
3.11	UV-Vis absorption spectrum of levodopa using PBS pH 7.4 as solvent.	63
3.12	Plot of absorbance against concentration of levodopa using PBS pH 7.4 as solvent.	64
3.13	Calibration curve of absorbance against concentration for levodopa at 280 nm using PBS pH 7.4 as solvent.	65
3.14	UV-Vis absorption spectrum of levodopa using deionized water as solvent.	66
3.15	Plot of absorbance against concentration of levodopa using deionized water as solvent.	67
3.16	Calibration curve of absorbance against concentration for levodopa at 280 nm using deionized water as solvent.	68
4.1	UV-Vis absorption spectra of SB, SB residue after removal of SWCNTs-SB from the SB solution, ethanol and SWCNTs-COOH.	79
4.2	Schematic drawing of the suggested non-covalent π -stacking interaction of SB with SWCNTs-COOH.	79
4.3	FTIR spectra of (A) free SB and (B) SB-loaded nanohybrid.	81
4.4	Raman spectra of (A) SWCNTs-COOH and (B) SB-loaded nanohybrid.	82
4.5	TEM micrographs of (A) SWCNTs-COOH before and (B) after SB conjugation.	83
4.6	FESEM micrographs of (A) SWCNTs-COOH and (B) SB-loaded nanohybrid.	83
4.7	Release profiles of SB from SWCNTs-COOH at pH 7.4 and pH 4.8.	84
4.8	Fits of the release data of SB from SWCNTs-COOH to the <i>pseudo</i> -first order and <i>pseudo</i> -second order kinetic models as well as to the parabolic equation for pH 7.4 (A-C) and pH 4.8 (D-F). The release kinetic behaviour of SB conformed well to <i>pseudo</i> -second order (B and E).	86

4.9	Cytotoxicity nature of SB, SWCNTs-SB and SWCNTs-COOH on normal fibroblast cells (A) 3T3, (B) MRC-5, as well as human cancer cells (C) HepG2 and (D) A549 after 72 hours of treatment at various concentrations.	87
5.1	UV-Vis absorption spectra of SB, MWCNTs-SB, and MWCNTs-COOH.	93
5.2	FTIR spectra of (A) MWCNTs-COOH, (B) SB, and (C) MWCNTs-SB nanohybrid.	95
5.3	Raman spectra of MWCNTs-COOH and MWCNTs-SB nanohybrid.	96
5.4	TGA thermograms of MWCNTs-COOH nanocarrier and MWCNTs-SB nanohybrid in nitrogen atmosphere.	97
5.5	FESEM images of (A) MWCNTs-COOH and (B) MWCNTs-SB nanohybrid.	98
5.6	Low resolution TEM images of (A) MWCNTs-COOH sample and (B) synthesized MWCNTs-SB nanohybrid.	98
5.7	Release profiles of SB from MWCNTs at pH 7.4 and pH 4.8 up to 1000 minutes.	99
5.8	Fitting data of SB from MWCNTs nanocarrier into PBS solutions at pH 7.4 and pH 4.8 using <i>pseudo</i> -first and <i>pseudo</i> -second order kinetics and parabolic diffusion model. The release of kinetic behaviour of SB from its nanocarrier conformed well to <i>pseudo</i> -second order.	101
5.9	Effect of SB, MWCNTs-COOH, and MWCNTs-SB nanohybrid on cell viability of human cancer cells (A) HepG2 and (B) A549 for 72 hours of treatment at various concentrations.	102
6.1	UV-Vis absorption spectra of pure BA, the supernatant of SWCNTs-BA conjugate, and SWCNTs-COOH.	107
6.2	Proposed reaction scheme for the functionalization of BA molecules onto the SWCNTs-COOH nanocarrier via π - π stacking interaction.	108
6.3	FTIR transmission spectra of SWCNTs-BA and BA.	109
6.4	TGA weight loss profiles of (A) SWCNTs-COOH and (B) SWCNTs-BA under nitrogen atmosphere.	110
6.5	PXRD patterns of (A) SWCNTs-COOH, (B) SWCNTs-BA, and (C) free BA.	111

6.6	(A) Raman spectra of the RBM region for SWCNTs-COOH and SWCNTs-BA. (B) Raman spectra D and G bands for SWCNTs-COOH and SWCNTs-BA.	112
6.7	FESEM images of the surfaces of (A) free BA in its crystallized form, (B) SWCNTs-COOH, and (C) SWCNTs-BA.	113
6.8	Release profiles of BA from SWCNTs-COOH nanocarrier into PBS solutions at pH 7.4 and 4.8. Inset shows release profiles of SWCNTs-BA for the first 60 minutes.	114
6.9	Fitting the data for BA released from SWCNTs-COOH nanocarrier into PBS solutions with specific pH values.	117
6.10	<i>In vitro</i> cytotoxicity study of (A) 3T3, (B) HepG2, and (C) A549 exposed to free BA, SWCNTs-COOH nanocarrier, and the SWCNTs-BA conjugate, respectively, at various concentrations after 72 hours of treatment. The data presented are mean \pm SD of triplicate values.	118
7.1	Chemical structure of betulinic acid, the oxidation product of betulin.	123
7.2	UV-Vis spectrophotometry of the original BA and BA residue after removal of loaded MWCNTs-COOH from the supernatant.	127
7.3	Suggested schematic drawing of the possible interaction of BA with oxidized MWCNTs.	128
7.4	FTIR spectroscopy of MWCNTs-COOH before and after loading with BA.	129
7.5	TGA and DTGA profiles of (A) oxidized MWCNTs before and (B) after loading with BA.	130
7.6	PXRD patterns of BA, MWCNTs-COOH and MWCNTs-BA.	131
7.7	FESEM photographs of (A) oxidized MWCNTs and (B) MWCNTs loaded with BA.	132
7.8	Release profiles of BA from oxidized MWCNTs into PBS solutions at pH 7.4 and 4.8 within (A) 100 minutes and (B) 1300 minutes.	134
7.9	Fits of BA release data for oxidized MWCNTs nanocarrier at pH 7.4 and 4.8 using <i>pseudo-first</i> , <i>pseudo-second</i> order kinetics, and parabolic diffusion model.	136

7.10	Cell viability of (A) normal mouse embryo fibroblast cells, (B) human lung cancer cells, and (C) human liver cancer cells treated with free BA, oxidized MWCNTs nanocarrier, and MWCNTs-BA nanocomposite for 72 hours. The data presented are mean \pm SD of triplicate samples and the difference was considered significant at P -value <0.05.	137
8.1	UV-Vis absorption spectra of pure levodopa, supernatant residue and SWCNTs-COOH.	143
8.2	Suggested π - π interaction between levodopa molecules and CNTs in a (A) sandwich or (B) parallel-displaced interaction.	144
8.3	FTIR spectra of (A) SWCNTs-COOH, (B) levodopa and (C) SWCNTs-levodopa nanohybrid.	146
8.4	Raman spectra of the SWCNTs-COOH nanocarrier and the SWCNTs-LD nanohybrid.	148
8.5	FESEM images of (A) SWCNTs-COOH and (B) SWCNTs-LD nanohybrid.	149
8.6	TEM micrographs of (A) SWCNTs-COOH and (B) SWCNTs-LD.	149
8.7	Release profiles of levodopa from SWCNTs-COOH into PBS solutions at pH 7.4 and pH 4.8.	150
8.8	Fitting data for the release of levodopa from SWCNTs-COOH to the <i>pseudo</i> -first order, <i>pseudo</i> -second order and the parabolic equation for pH 7.4 (A-C) and pH 4.8 (D-F).	152
8.9	MTT assay of PC12 cell lines after 24, 48 and 72 hours of treatment with levodopa, SWCNTs-COOH and SWCNTs-LD nanohybrid at different concentrations. The optical density is directly correlated to the number of living cells. The data are shown as means \pm SD from three individual experiments.	154
9.1	FTIR spectra of the (A) SWSB, (B) T20, (C) T20-coated SWCNTs-SB, (D) T80, (E) T80-coated SWCNTs-SB, (F) PEG, (G) PEG-coated SWCNTs-SB, (H) CHI, and (I) CHI-coated SWCNTs-SB along with their chemical structures.	161
9.2	Raman spectra of the (A) SWCNTs-COOH, (B) SWCNTs-SB, (C) SWSB-T20, (D) SWSB-T80, (E) SWSB-PEG, and (F) SWSB-CHI nanocomposites.	164
9.3	FESEM images of (A) SWCNTs-COOH, (B) SWSB-T20, (C) SWSB-T80, (D) SWSB-PEG, and (E) SWSB-CHI at magnification 100 kx.	166

9.4	Release profile of SB from (A) SWCNTs-SB, (B) SWSB-PEG, (C) SWSB-T80, (D) SWSB-CHI, and (E) SWSB-T20 at pH 7.4. Inset shows the initial release of the nanocomposites at pH 7.4 in the first 100 minutes.	167
9.5	Fits of the release data of SB from (A) SWCNTs-SB, (B) SWSB-T20, (C) SWSB-T80, (D) SWSB-PEG, and (E) SWSB-CHI at pH 7.4 using <i>pseudo</i> -second-order kinetic model.	170
9.6	Cell viability of 3T3 cell line treated with SWSB-T20, SWSB-T80, SWSB-PEG, and SWSB-CHI for 72 hours. Cell viability is calculated as a percentage of absorbance of treated cells over absorbance of untreated cells. Data are shown as means \pm standard deviation from three separate experiments ($n=3$).	171
10.1	Molecular structure of Tween 20 and Tween 80, where $w + x + y + z = 20$; polyethylene glycol and chitosan.	175
10.2	FTIR spectra of (A) T20-coated SWCNTs-BA, (B) T80-coated SWCNTs-BA, (C) PEG-coated SWCNTs-BA and (D) CHI-coated SWCNTs-BA.	180
10.3	Raman spectra for (A) carboxylated SWCNTs, (B) SWCNTs-BA, (C) SWBA-T20, (D) SWBA-T80, (E) SWBA-PEG, and (F) SWBA-CHI.	183
10.4	HR TEM images of the (A) carboxylated SWCNTs and (B) BA-loaded SWCNTs. The arrow indicates possible location of BA molecule being encapsulated in the nanotubes.	185
10.5	FESEM images of the (A) carboxylated SWCNTs and biopolymer-coated SWCNTs-BA nanocomposites; (B) T20-coated SWCNTs-BA, (C) T80-coated SWCNTs-BA, (D) PEG-coated SWCNTs-BA and (E) CHI-coated SWCNTs-BA.	186
10.6	Comparative drug release kinetics of BA from biopolymer-coated SWCNTs-BA nanocomposites into PBS solution at pH 7.4. (A) Burst release; (B) slow and sustained release.	188
10.7	<i>In vitro</i> cell viability of 3T3 cells treated with (A) SWBA-T20, (B) SWBA-T80, (C) SWBA-PEG, and (D) SWBA-CHI at different concentrations for 24, 48 and 72 hours. Error bars represent mean \pm SD for $n = 3$.	190

LIST OF APPENDICES

Appendix		Page
A	Workflow of the use of carboxylated CNTs for drug delivery system	236
B	TGA thermograms of (A) SWCNTs-COOH nanocarrier and (B) SWCNTs-SB nanohybrid in nitrogen atmosphere	237
C	TGA thermograms of (A) SWCNTs-COOH nanocarrier and (B) SWCNTs-LD nanohybrid in nitrogen atmosphere	238
D	The 96 wells microtiter plate	239
E	IC ₅₀ calculation for 3T3 by extrapolation (Chapter 7)	240
F	IC ₅₀ calculation for A549 by extrapolation (Chapter 7)	241
G	IC ₅₀ calculation for HepG2 by extrapolation (Chapter 7)	242
H	Summary	243

LIST OF ABBREVIATIONS

AFM	Atomic force microscopy
ANG	Angiopep-2
ANOVA	Analysis of variance
ATCC	American Type Culture Collection
AZ	Azithromycin
A549	Human lung adenocarcinoma epithelial cell line
BA	Betulinic acid
BET	Brunauer-Emmett-Teller
BSA	Bovine serum albumin
CAR	Carvedilol
CHI	Chitosan
CIS	Cisplatin
CLC	Carbon nanotubes-liposomes conjugate
CNTs	Carbon nanotubes
DAU	Daunorubicin
D-band	Disorder-induced mode
DL	Drug loading
DMEM	Dulbecco's Modified Eagle Medium
DMF	Dimethylformamide
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DOX	Doxurubicin
DPI	Dry powder inhaler
e.g.	Exempli gratia
EGF	Epidermal growth factor
et al.	Et alia
etc.	Et cetera
FA	Folic acid
FBS	Foetal bovine serum
f-CNTs	Functionalized carbon nanotubes
FDA	United States Food and Drug Administration
FESEM	Field emission scanning electron microscopy
FITC	Fluorescein isothiocyanate
FTIR	Fourier transform infrared spectroscopy
G-band	Tangential displacement mode
GEM	Gemcitabine
HA	Hyaluronan
HCC	Hydrophilic carbon clusters
HepG2	Human liver hepatocellular carcinoma cell line
HUVEC	Human umbilical vein endothelial cells
IC ₅₀	Half maximal inhibitory concentration
i.e.	Id est
IR	Infrared
KBr	Potassium bromide
LD	Levodopa
LRP	Lipoprotein receptor-related protein
MRC-5	Normal human lung cell line

MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MWCNTs	Multiwalled carbon nanotubes
MWCNTs-BA	Betulinic acid-loaded multiwalled carbon nanotubes
MWCNTs-COOH	Carboxylic acid-functionalized multiwalled carbon nanotubes
MWCNTs-SB	Silibinin-loaded multiwalled carbon nanotubes
NIR	Near Infrared
NMR	Nuclear magnetic resonance
OD	Optical density
PAMAM	Polyamidoamine
PBS	Phosphate buffered saline
PC12	Rat neuronal cell line
PD	Parkinson's disease
PEG	Polyethylene glycol
PL	Phospholipid
PLGA	Poly(lactide- <i>co</i> -glycolide) acid
PLL	Poly-L-lysine
PTX	Paclitaxel
PXRD	Powder X-ray diffractometry
QD	Quantum dot
RBM	Radial breathing mode
rpm	Rotation per minute
SB	Silibinin
S_{BET}	Specific surface area
SD	Standard deviation
SEM	Scanning electron microscopy
STEM	Z-contrast scanning transmission electron microscopy
STM	Scanning tunnelling microscopy
SWCNTs	Single walled carbon nanotubes
SWCNTs-BA	Betulinic acid-loaded single walled carbon nanotubes
SWCNTs-COOH	Carboxylic acid-functionalized single walled carbon nanotubes
SWCNTs-LD	Levodopa-loaded single walled carbon nanotubes
SWCNTs-SB	Silibinin-loaded single walled carbon nanotubes
TEM	Transmission electron microscopy
TGA	Thermal gravimetry
T20	Tween 20
T80	Tween 80
UV-Vis	Ultraviolet-visible spectrophotometer
W	Weight
XPS	X-ray photoelectron spectroscopy
XRD	X-ray diffractometry
3T3	Mouse fibroblast cell line

CHAPTER 1

INTRODUCTION

1.1 Background of Study

There are various definitions currently circulating when it comes to the term nanotechnology. The prefix “nano” is actually originated from the Greek word “nanos” for dwarf and technology refers to the application of science in a particular subject (Buzea *et al.*, 2007). One nanometer (nm) is equal to one billionth of a meter and a meter is approximately 39 inches long. According to the declaration made by the United States National Nanotechnology Initiative, nanotechnology involves research and development at the atomic, molecular, or macromolecular levels at dimensions between 1 and 100 nm to create structures, devices, and systems that are enabled for novel applications.

In recent years, nanobiotechnology (a combination of nanotechnology and biotechnology) especially in medicine, or the so-called nanomedicine, has emerged as one of the most advanced and promising areas in drug delivery application. The application of nanotechnology in drug delivery involves the use of carriers and therapeutic agents. Nanoscale drug carriers can significantly enhance the bioavailability and therapeutic efficacy of drugs with reduced side effects. Therapeutic agents are drugs or biologically active materials (*e.g.* nucleic acids and proteins) which can be entrapped, intercalated, encapsulated, dissolved, adsorbed, or attached onto the drug carriers, which can then be tailored for controlled and sustained-release formulations.

1.2 Problem Statement

The polyphenolic phytochemical silibinin (SB, 2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-6-(3,5,7-trihydroxy-4-oxobenzopyran-2-yl) benzodioxin, Figure 1.1) is the main constituent of the silymarin mixture extracted from the seeds, fruits, and leaves of milk thistle (*Silybum marianum* L.) plant (Verschoyle *et al.*, 2008). This lignoflavonoid has been used traditionally for more than 2000 years as herbal remedy for the treatment of hepatic disorders (Hruby *et al.*, 1983). Even though SB has poor oral bioavailability due to poor aqueous solubility, most of the findings in the past demonstrated that SB exhibits anti-proliferative, anti-inflammatory, anti-fibrotic, anti-oxidant, anti-carcinogenic, membrane stabilizing and liver regeneration effects (Karim *et al.*, 2013; Sonnenbichler *et al.*, 1999) in both pharmacological and experimental research.




Figure 1.1. Chemical structure of silibinin.

Betulinic acid (BA, 3 β -hydroxy-lup-20(29)-en-28-oic acid, Figure 1.2) is a naturally occurring pentacyclic lupane-type triterpene extracted from numerous botanical sources found widely distributed in the plant kingdom. It has been used traditionally as a folk remedy by the Native Americans to treat intestinal problems like dysentery and diarrhea. Recent studies reported that BA possesses many favourable therapeutic activities such as anticancer, hepatoprotective potential, antimalarial, anti-inflammatory, antihuman immunodeficiency virus, anthelmintic, and antioxidant effects (Baratto *et al.*, 2013; Jain *et al.*, 2012). BA was also well known for its high selective cytotoxic activity against human melanoma derived cell lines (Kommera *et al.*, 2010) as well as other types of cancerous tumours (Sun *et al.*, 2013; Chintharlapalli *et al.*, 2011). Healthy, normal cells like peripheral blood lymphoblasts, melanocytes, normal human fibroblasts, and astrocytes were also reported to be resistant against BA treatment *in vitro* (Selzer *et al.*, 2000). However, its optimum potential is greatly limited by poor solubility in aqueous solvents. As such, an ideal delivery system can further enhance the bioavailability of BA as a potent anticancer agent.




Figure 1.2. Molecular structure of betulinic acid.

Levodopa (LD, 3-(3,4-dihydroxyphenyl)-L-alanine, Figure 1.3), an anti-Parkinson drug, is the most effective and widely prescribed oral administration due to its ability to cross the blood brain barrier. However, long term responsive patients treated with LD therapy may experience a decrease in the duration of responsiveness to the treatment and resulting in motor fluctuation (dyskinesia) side effects (Modi *et al.*, 2009).

Moreover, once LD is administered orally into the body, the drug is immediately metabolized and only a small amount of drug reaches the central nervous system. To prevent LD from being rapidly metabolized before it reaches the brain, carbidopa, an inhibitor of dopamine decarboxylase, is commonly used in combination with LD to enhance the effectiveness of LD peripherally (Okereke *et al.*, 2004). Therefore, in order to achieve the desired effect with a lower therapeutic dose of LD, one will have to take several combinations of these medications which further increases inconvenience in patients.




Figure 1.3. Structure of levodopa.

Current methods of conventional drugs administered via liquids or pills are generally less efficient and suffered from poor biodistribution, low solubility, long term toxicity, and limited drug efficacy (Del Valle *et al.*, 2009). This has caused the pharmaceutical industry to develop novel drug delivery systems using a wide range of biocompatible drug carriers with the aim to improve therapeutic efficacy and reduced toxicity. In meeting this demand, various forms of efficient and biocompatible drug delivery systems have been developed extensively and can be generally classified into four major categories: nanomaterials (Saifullah *et al.*, 2013; Hariharan *et al.*, 2012), viral carriers (Teunissen *et al.*, 2013; Zeng *et al.*, 2013), organic cationic compounds (Tseng *et al.*, 2013; Salomon and Ehrhardt, 2012), and recombinant proteins (Hofer *et al.*, 2012; Teng *et al.*, 2011).

Nanomaterials such as CNTs have been receiving considerable amount of attention as a new, non-viral carrier alternative (Ji *et al.*, 2012; Cheng *et al.*, 2011a; Li *et al.*, 2011a) compared to viral and cationic carrier. These allotropes of carbons are extensively studied and investigated as novel drug delivery vehicles due to their good biocompatibility, ultrahigh surface area, good mechanical strength yet ultralight weight, low cytotoxicity, and excellent chemical and thermal stability. Furthermore, their outer surface can be chemically functionalized with biocompatible materials (Zheng *et al.*, 2013), whilst inner volume allows the loading of small biomolecules such as proteins and genes for effective drug delivery (Luo *et al.*, 2011). Recently, it was reported that chemically functionalized CNTs can be utilized as a novel form of drug carrier by attaching different range of functional groups to their sidewalls (Liu *et al.*, 2008). The research team discovered that the functionalized CNTs were able to cross cell barriers in mice through the enhanced permeability and retention effect without causing any harm to the normal cells. Equipped with all these unique advantages of CNTs and their tremendous breakthroughs in nanomedicine, it is no doubt that CNTs can be used as a promising novel drug delivery system for advanced therapeutic treatment. Therefore, carboxylated CNTs were selected as the nanocarrier for effective delivery of SB, BA and LD in this study.

1.3 Scope of Study

The present study was conducted to develop and determine the physico-chemical properties of carboxylated CNTs-based drug delivery formulation for SB, BA and LD. Secondly, drug loading and release profiles of the synthesized nanohybrids were studied in human body-simulated phosphate buffered saline (PBS) solutions at pH 7.4 and 4.8. pH 7.4 was chosen to demonstrate the drug release in physiological environment, whereas pH 4.8 was selected to mimic the acidic condition of human stomach after food. Finally, in order to assess the cytotoxic characteristics of the drug-loaded nanohybrids, human cancer cell lines HepG2 (human liver hepatocellular carcinoma cell lines) and A549 (human lung adenocarcinoma epithelial cell lines) were used in comparison with normal, healthy cell lines MRC-5 (normal human lung cell lines), 3T3 (mouse fibroblast cell lines) and PC12 (rat neuronal cell lines). In addition to that, further coating steps were taken as an attempt to mask the cytotoxicity of the drug-loaded CNTs nanohybrids and the coating effects were determined on 3T3 cells in detailed. This study however, does not cover the biological aspect of specific cellular uptake mechanism of the resulting nanohybrids and cell interactions due to constraints imposed by time, cost and availability of materials.

1.4 Hypotheses

Carboxylated CNTs can be loaded with SB, BA and LD non-covalently via $\pi-\pi$ stacking hydrogen bonding and hydrophobic interactions for advanced drug delivery. The developed CNTs drug-loaded nanohybrids demonstrated controlled and sustained-release properties with enhanced efficiency of the *in vitro* delivery of SB, BA and LD compared with the pure drugs. Due to the carboxylic acid (-COOH) functional groups of carboxylated CNTs which facilitate their solubility in physiological environment, the drug-loaded nanohybrids are not acutely toxic in healthy cells *in vitro*. In addition, they are capable of inhibiting the growth of cancer cells *in vitro* by immobilizing the drugs on the outer wall or by encapsulation inside the nanotubes.

1.5 Objectives

The purpose of the present study is to develop drug-loaded carboxylated CNTs formulation for effective drug delivery. The specific objectives are as follows:

- a) to synthesize and characterize the nanohybrids, namely SWCNTs-SB, MWCNTs-SB, SWCNTs-BA, MWCNTs-BA, SWCNTs-LD, SWSB-T20, SWSB-T80, SWSB-PEG, SWSB-CHI, SWBA-T20, SWBA-T80, SWBA-PEG and SWBA-CHI;
- b) to investigate the drug loading and release profile of the synthesized nanohybrids at two different pH levels (*i.e.* PBS solutions at pH 7.4 and pH 4.8);
- c) to study the cytotoxic activity of the synthesized nanohybrids in normal cell lines (*i.e.* 3T3, MRC-5 and PC12) and human cancer cell lines (*i.e.* HepG2 and A549); and
- d) to examine the use of the coating agents in the context of the drug release characteristic and cytotoxic activity in 3T3 cell lines.

REFERENCES

- Abi, T. G., Karmakar, T., and Taraphder, S. (2013). Proton affinity of polar amino acid sidechain analogues anchored to the outer wall of single walled carbon nanotubes. *Computational and Theoretical Chemistry*, 1010, 53–66.
- Abu-Dahab, R., Schfer, U. F., and Lehr, C. M. (2001). Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. *European Journal of Pharmaceutical Sciences*, 14(1), 37–46.
- Abuilaiwi, F. A., Laoui, T., Al-Harthi, M., and Atieh, M. A. (2010). Modification and functionalization of multiwalled carbon nanotube (MWCNT) via Fischer esterification. *The Arabian Journal for Science and Engineering*, 35(1), 37–48.
- Adeli, M., Hakimpoor, F., Ashiri, M., Kabiri, R., and Bavadi, M. (2011). Anticancer drug delivery systems based on noncovalent interactions between carbon nanotubes and linear-dendritic copolymers. *Soft Matter*, 7(8), 4062–4070.
- Addolorato, G., Di Campli, C., Simoncini, M., Pasini, P., Nardo, B., Cavallari, A., Pola, P., Roda, A., Gasbarrini, G., and Gasbarrini A. (2001). Oxygen free radical production in rat liver: dose-related effect of ethanol on reperfusion injury. *Digestive Diseases and Sciences*, 46, 1057–1066.
- Adesanwo, J. K., Makinde, O. O., and Obafemi, C. A. (2013). Phytochemical analysis and antioxidant activity of methanol extract and betulinic acid isolated from the roots of *Tetracera potatoria*. *Journal of Pharmacy Research*, 6(9), 903–907.
- Aghabozorg, H. R., Kish, S. S., and Rashidi, A. M. (2010). Solubility of functionalized carbon nanotubes in different solvents. *Journal of Applied Chemical Researches*, 3(12), 29–33.
- Albini, A., Mussi, V., Parodi, A., Ventura, A., Principi, E., Tegami, S., Rocchia, M., Francheschi, E., Sogno, I., Cammarota, R., Finzi, G., Sessa, F., Noonan, D. M., and Valbusa, U. (2010). Interactions of singlewall carbon nanotubes with endothelial cells. *Nanomedicine: Nanotechnology, Biology, and Medicine*, 6(2), 277–288.
- Ali, M. (2010). Pulmonary drug delivery. In Kulkarni, V. S. *Handbook of Non-Invasive Drug Delivery Systems* (pp. 209–246). United States of America: Elsevier Inc.
- Alpatova, A. L., Shan, W., Babica, P., Upham, B. L., Rogensues, A. R., Masten, S. J., Drown, E., Mohanty, A. K., Alocilja, E. C., and Tarabara, V. V. (2010). Single-walled carbon nanotubes dispersed in aqueous media via non-covalent functionalization: effect of dispersant on the stability, cytotoxicity, and epigenetic toxicity of nanotube suspensions. *Water Research*, 44(2), 505–520.
- Al-Qadi, S., Grenha, A., and López, C. R. (2011). Microspheres loaded with polysaccharide nanoparticles for pulmonary delivery: preparation, structure and surface analysis. *Carbohydrate Polymers*, 86(1), 25–34.

American Cancer Society. (2015). *Cancer Facts & Figures 2015*. Atlanta: American Cancer Society Inc.

Arepalli, S., Nikolaev, P., Gorelik, O., Hadjiev, V. G., Holmes, W., Files, B., and Yowell, L. (2004). Protocol for the characterization of single-wall carbon nanotube material quality. *Carbon*, 42(8-9), 1783-1791.

Arora, A., Prausnitz, M. R., and Mitragotri, S. (2008). Micro-scale devices for transdermal drug delivery. *International Journal of Pharmaceutics*, 364(2), 227-236.

Ashurst, I., Malton, A., Prime, D., and Sumby, B. (2000). Latest advances in the development of dry powder inhalers. *Pharmaceutical Science & Technology Today*, 3(7), 246-256.

Azarmi, S., Roa, W. H., and Löbenberg, R. (2008). Targeted delivery of nanoparticles for the treatment of lung diseases. *Advanced Drug Delivery Reviews*, 60(8), 863-875.

Bachmatiuk, A., Börrnert, F., Schäffel, F., Zaka, M., Martynkowa, G. S., Placha, D., Schönfelder, R., Costa, P. M. F. J., Ioannides, N., Warner, J. H., Klingeler, R., Buchner, B., and Rümmeli, M. H. (2010). The formation of stacked-cup carbon nanotubes using chemical vapor deposition from ethanol over silica. *Carbon*, 48(11), 3175-3181.

Bajaj, A. and Desai, M. (2006). Challenges and strategies in novel drug delivery technologies. *Pharma Times*, 38(4), 12-16.

Bangham, A. D. and Horne, R. W. (1964). Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. *Journal of Molecular Biology*, 8, 660-668.

Barahuie, F., Hussein, M. Z., Hussein-Al-Ali, S. H., Arulselvan, P., Fakurazi, S., and Zainal, Z. (2013). Preparation and controlled-release studies of a protocatechuic acid-magnesium/aluminium layered double hydroxide nanocomposite. *International Journal of Nanomedicine*, 8, 1975-1987.

Baratto, L. C., Porsani, M. V., Pimentel, I. C., Netto, A. B. P., Paschke, R., and Oliveira, B. H. (2013). Preparation of betulinic acid derivatives by chemical and biotransformation methods and determination of cytotoxicity against selected cancer cell lines. *European Journal of Medicinal Chemistry*, 68, 121-131.

Bari, H. (2010). A prolonged release parenteral drug delivery system – an overview. *International Journal of Pharmaceutical Sciences Review and Research*, 3(1), 1-11.

Bear, J. C., McNaughton, P. D., Jurkschat, K., Crossley, A., Aldous, L., Compton, R. G., Mayes, A. G., and Wildgoose, G. G. (2012). Synthesis and characterization of carbon nanotubes covalently functionalized with amphiphilic polymer coated superparamagnetic nanocrystals. *Journal of Colloid and Interface Science*, 383(1), 110-117.

- Beasley, V. R. and Buck, W. B. (1980). Acute ethylene glycol toxicosis: a review. *Veterinary and Human Toxicology*, 22(4), 255–263.
- Beg, S., Rizwan, M., Sheikh, A. M., Hasnain, M. S., Anwer, K., and Kohli, K. (2011). Advancement in carbon nanotubes: basics, biomedical applications and toxicity. *Journal of Pharmacy and Pharmacology*, 63(2), 141–163.
- Belin, T. and Epron, F. (2005). Characterization methods of carbon nanotubes: a review. *Materials Science and Engineering: B*, 119(2), 105–118.
- Benyettou, F., Hardouin, J., Lecouvey, M., Jouni, H., and Mottle, L. (2012). PEGylated versus non-PEGylated $\gamma\text{Fe}_2\text{O}_3@\text{alendronate}$ nanoparticles. *Journal of Bioanalysis & Biomedicine*, 4(3), 039–045.
- Berlin, J. M., Leonard, A. D., Pham, T. T., Sano, D., Marcano, D. C., Yan, S., Fiorentino, S., Milas, Z. L., Kosynkin, D. V., Price, B. K., Luente-Schultz, R. M., Wen, X., Raso, M. G., Craig, S. L., Tran, H. T., Myers, J. N., and Tour, J. M. (2010). Effective drug delivery, *in vitro* and *in vivo*, by carbon-based nanovectors noncovalently loaded with unmodified paclitaxel. *ACS Nano*, 4(8), 4621–4636.
- Bernkop-Schnürch, A. (2005). Mucoadhesive systems in oral drug delivery. *Drug Discovery Today*, 2(1), 83–87.
- Bethune, D. S., Kiang, C. H., de Vries, M. S., Gorman, G., Savoy, R., Vazquez, J., and Beyers, R. (1993). Cobalt catalysed growth of carbon nanotubes with single-atomic-layer walls. *Nature*, 363(6430), 605–607.
- Bhatnagar, I., Venkatesan, J., and Kim, S. K. (2014). Polymer functionalized single walled carbon nanotubes mediated drug delivery of gliotoxin in cancer cells. *Journal of Biomedical Nanotechnology*, 10(1), 120–130.
- Bhavane, R., Karathanasis, E., and Annapragada, A. V. (2003). Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery. *Journal of Controlled Release*, 93(1), 15–28.
- Bhirde, A. A., Patel, S., Gavard, J., Zhang, G., Sousa, A. A., Masedunskas, A., Leapman, R. D., Weigert, R., Gutkind, J. S., and Rusling, J. F. (2009). Targeted killing of cancer cells *in vivo* and *in vitro* with EGF-directed carbon nanotubebased drug delivery. *ACS Nano*, 3(2), 307–316.
- Bhirde, A. A., Patel, S., Sousa, A. A., Patel, V., Molinolo, A. A., Ji, Y., Leapman, R. D., Gutkind, J. S., and Rusling, J. F. (2010). Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. *Nanomedicine*, 5(10), 1535–1546.
- Bianco, A., Kostarelos, K., and Prato, M. (2005). Applications of carbon nanotubes in drug delivery. *Current Opinion in Chemical Biology*, 9(6), 674–679.
- Boisseau, P. and Loubaton, B. (2011). Nanomedicine, nanotechnology in medicine. *Comptes Rendus Physique*, 12(7), 620–636.

- Bokobza, L. and Zhang, J. (2012). Raman spectroscopic characterization of multiwall carbon nanotubes and of composites. *eXPRESS Polym Lett*, 6(7), 601-608.
- Borges, A. C., Jayakrishnan, A., Bourban, P. E., Plummer, C. J. G., Pioletti, D. P., and Månsen, J. A. E. (2012). Synthesis and photopolymerization of tween 20 methacrylate/N-vinyl-2-pyrrolidone blends. *Materials Science and Engineering C*, 32(8), 2235-2241.
- Boyapally, H., Nukala, R. K., Bhujbal, P., and Douroumis, D. (2010). Controlled release from directly compressible theophylline buccal tablets. *Colloids and Surfaces B: Biointerfaces*, 77(2), 227-233.
- Brunauer, S., Emmett, P. H., and Teller, E. (1938). Adsorption of gases in multimolecular layers. *Journal of the American Chemical Society*, 60(2), 309–319.
- Buzea, C., Blandino, I. I. P., and Robbie, K. (2007). Nanomaterials and nanoparticles: sources and toxicity. *Biointerphases*, 2(4), MR17–MR172.
- Canevari, M., Castagliuolo, I., Brun, P., Cardin, M., Schiavon, M., Pasut, G., and Veronese, F. M. (2009). Poly(ethyleneglycol)-mesalazine conjugate for colon specific delivery. *International Journal of Pharmaceutics*, 368(1-2), 171-177.
- Cao, X., Deng, W., Fu, M., Zhu, Y., Liu, H., Wang, L., Zeng, J., Wei, Y., Xu, X., and Yu, J. (2013). Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: *in vitro* release kinetics and *in vitro/in vivo* correlations in beagle dogs. *European Journal of Pharmaceutical Sciences*, 48(1-2), 64–71.
- Cao, Z., Tong, R., Mishra, A., Xu, W., Wong, C. L., Cheng, J., and Lu, Y. (2009). Reversible cell-specific drug delivery with aptamer-functionalized liposomes. *Angewandte Chemie*, 48(35), 6494–6498.
- Castillo, J. J., Rindzevicius, T., Novoa, L. V., Svendsen, W. E., Rozlosnik, N., Boisen, A., Escobar, P., Martínez, F. and Castillo-León, J. (2013). Non-covalent conjugates of single-walled carbon nanotubes and folic acid for interaction with cells over-expressing folate receptors. *Journal of Materials Chemistry B*, 1(10), 1475–1481.
- Chang, P. R., Zheng, P., Liu, B., Anderson, D. P., Yu, J., and Ma, X. (2011). Characterization of magnetic soluble starch-functionalized carbon nanotubes and its application for the adsorption of the dyes. *Journal of Hazardous Materials*, 186(2-3), 2144–2150.
- Chen, S., Hu, S., Smith, E. F., Ruenraroengsak, P., Thorley, A. J., Menzel, R., Goode, A. E., Ryan, M. P., Tetley, T. D., Porter, A. E., and Shaffer, M. S. (2014). Aqueous cationic, anionic and non-ionic multi-walled carbon nanotubes, functionalised with minimal framework damage, for biomedical application. *Biomaterials*, 35(17), 4729–4738.

- Chen, Q., Kaneko, T., and Hatakeyama, R. (2011a). Characterization of pulse-driven gas-liquid interfacial discharge plasmas and application to synthesis of gold nanoparticle-DNA encapsulated carbon nanotubes. *Current Applied Physics*, 11(5), S63–S66.
- Chen, Z., Pierre, D., He, H., Tan, S., Pham-Huy, C., Hong, H., and Huang, J. (2011b). Adsorption behavior of epirubicin hydrochloride on carboxylated carbon nanotubes. *International Journal of Pharmaceutics*, 405(1-2), 153–161.
- Cheng, J., Meziani, M. J., Sun, Y. P., and Cheng, S. H. (2011a). Poly(ethylene glycol)-conjugated multi-walled carbon nanotubes as an efficient drug carrier for overcoming multidrug resistance. *Toxicology and Applied Pharmacology*, 250(2), 184–193.
- Cheng, Y., Shao, Y., and Yan, W. (2011b). Solubilities of betulinic acid in thirteen organic solvents at different temperatures. *Journal of Chemical & Engineering Data*, 56, 4587–4591.
- Cherukuri, P., Bachilo, S. M., Litovsky, S. H., and Weisman, R. B. (2004). Near-infrared fluorescence microscopy of single-walled carbon nanotubes in phagocytic cells. *Journal of the American Chemical Society*, 126(48), 15638–15639.
- Cheung, C. W. Y., Gibbons, N., Johnson, D. W., and Nicol, D. L. (2010). Silibinin – a promising new treatment for cancer. *Anticancer Agents in Medicinal Chemistry*, 10, 186–195.
- Chidawanyika, W. and Nyokong, T. (2010). Characterization of amine functionalized single-walled carbon nanotube-low symmetry phthalocyanine conjugates. *Carbon*, 48(10), 2831– 2838.
- Chigumbu, N., Iyuke, S., Pillay, V., and Ndlovu, S. (2012). *In vitro* evaluation of the physicochemical effects of drug loaded carbon nanotubes on toxicity. *Journal of Nanomedicine and Nanotechnology*, 3(4), 1–7.
- Chintharlapalli, S., Papineni, S., Lei, P., Pathi, S., and Safe, S. (2011). Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent down regulation of specificity proteins (Sp) transcription factors. *BMC Cancer*, 11, Article 371.
- Cho, H. J., Suh, D. S., Moon, S. H., Song, Y. J., Yoon, M. S., Park, D. Y., Choi, K. U., Kim, Y. K., and Kim, K. H. (2013). Silibinin inhibits tumor growth through down regulation of extracellular signal regulated kinase and Akt *in vitro* and *in vivo* in human ovarian cancer cells. *Journal of Agricultural and Food Chemistry*, 61(17), 4089–4096.
- Chono, S., Fukuchi, R., Seki, T., and Morimoto, K. (2009). Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. *Journal of Controlled Release*, 137(2), 104–109.

- Cichewicz, R. H. and Kouzi, S. A. (2004). Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer. *Medicinal Research Reviews*, 24(1), 90–114.
- Căntă-Pînzaru, S., Dehelean, C. A., Soica, C., Culea, M., and Borcan, F. (2012). Evaluation and differentiation of the Betulaceae birch bark species and their bioactive triterpene content using analytical FT-vibrational spectroscopy and GC-MS. *Chemistry Central Journal*, 6(1), article 67.
- Ciobotaru, C. C., Damian, C. M., Polosan, S., Matei, E., and Iovu, H. (2014). Covalent functionalization of single walled carbon nanotubes with doxorubicin for controlled drug delivery systems. *Digest Journal of Nanomaterials and Biostructures*, 9(1), 413–422.
- Clementi, A., Aversa, M. C., Corsaro, C., Spooren, J., Stanganelli, R., O'Connor, C., McNamara, M., and Mazzaglia, A. (2011). Synthesis and characterization of a colloidal novel folic acid- β -cyclodextrin conjugate for targeted drug delivery. *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, 69(3-4), 321–325.
- Constantinides, P. P., Chaubal, M. V., and Shorr, R. (2008). Advances in lipid nanodispersions for parenteral drug delivery and targeting. *Advanced Drug Delivery Reviews*, 60(6), 757-767.
- Constantino, H. R., Illum, L., Brandt, G., Johnson, P. H., and Quay S. C. (2007). Intranasal delivery: physicochemical and therapeutic aspects. *International Journal of Pharmaceutics*, 337(1-2), 1-24.
- Crewe, A. V., Wall, J., and Lanomore, J. (1970). Visibility of single atoms. *Science*, 168(3937), 1338–1340.
- Crivellato, E., Beltrami, C. A., Mallardi, F., and Ribatti, D. (2003). Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. *British Journal of Haematology*, 123(1), 19-21.
- Csaba, N., Garcia-Fuentes, M., and Alonso, M. J. (2009). Nanoparticles for nasal vaccination. *Advanced Drug Delivery Reviews*, 61(2), 140-157.
- Dai, H. (2002). Carbon nanotubes: opportunities and challenges. *Surface Science*, 500(1-3), 218–241.
- Dai, L., Li, D., Cheng, J., Liu, J., Deng, L. H., Wang, L. Y., Lei, J. D., and He, J. (2014). Water soluble multiarm-polyethylene glycol-betulinic acid prodrugs: design, synthesis, and *in vivo* effectiveness. *Polymer Chemistry*, 5, 5775-5783.
- Dalmasso, P. R., Pedano, M. L., and Rivas, G. A. (2012). Dispersion of multi-wall carbon nanotubes in polyhistidine: characterization and analytical applications. *Analytica Chimica Acta*, 710, 58–64.

- Dang, Z., Qian, K., Ho, P., Zhu, L., Lee, K. H., Huang, L., and Chen, C. H. (2012). Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants. *Bioorganic and Medicinal Chemistry Letters*, 22(16), 5190–5194.
- Daniher, D. I. and Zhu, J. (2008). Dry powder platform for pulmonary drug delivery. *Particuology*, 6(4), 225-238.
- Darabi, H. R., Roozkhosh, A., Tehrani, M. J., Aghapoor, K., Sayahi, H., Balavar, Y., and Mohsenzadeh, F. (2014). Characterization of ester- or thioamide-functionalized single-walled carbon nanotube-azithromycin conjugates. *Applied Surface Science*, 288, 122–129.
- Darabi, H. R., Tehrani, M. J., Aghapoor, K., Mohsenzadeh, F., and Malekfar, R. (2012). A new protocol for the carboxylic acid sidewall functionalization of single-walled carbon nanotubes. *Applied Surface Science*, 258(22), 8953–8958.
- Dash, S., Murthy, P. N., Nath, L., and Chowdhury, P. (2010). Kinetic modelling on drug release from controlled drug delivery systems. *Acta Poloniae Pharmaceutica*, 67(3), 217-223.
- Date, A. A. and Nagarsenker, M. S. (2008). Parenteral microemulsions: an overview. *International Journal of Pharmaceutics*, 355(1-2), 19-30.
- Datsyuk, V., Kalyva, M., Papagelis, K., Parthenios, J., Tasis, D., Siokou, A., Kallitsis, I., and Galiotis, C. (2008). Chemical oxidation of multiwalled carbon nanotubes. *Carbon*, 46(6), 833–840.
- Dehelean, C. A., Feflea, S., Ganta, S., and Amiji, M. (2011). Anti-angiogenic effects of betulinic acid administered in nanoemulsion formulation using chorioallantoic membrane assay. *Journal of Biomedical Nanotechnology*, 7(2), 1–8.
- Del Maestro, R., Thaw, H. H., Björk, J., Planker, M., and Arfors, K. E. (1980). Free radicals as mediators of tissue injury. *Acta Physiologica Scandinavica Supplementum*, 492, 43-57.
- Del Valle, E. M. M., Galán, M. A., and Carbonell, R. G. (2009). Drug delivery technologies: the way forward in the new decade. *Industrial and Engineering Chemistry Research*, 48(5), 2475–2486.
- Dittmer, S., Olofsson, N., Weis, J. E., Nerushev, O. A., Gromov, A. V., and Campbell, E. E. B. (2008). *In situ* Raman studies of single-walled carbon nanotubes grown by local catalyst heating. *Chemical Physics Letters*, 457(1), 206-210.
- Dolatabadi, J. E. N., Omidi, Y., and Losic, D. (2011). Carbon nanotubes as an advanced drug and gene delivery nanosystem. *Current Nanoscience*, 7(3), 297–314.
- Dong, C., Campell, A. S., Eldawud, R., Perhinschi, G., Rojanasakul, Y., and Dinu, C. Z. (2013). Effects of acid treatment on structure, properties and biocompatibility of carbon nanotubes. *Applied Surface Science*, 264, 261–268.

- Dong, L., Yan, L., Hou, W. G., and Liu, S. J. (2010). Synthesis and release behavior of composites of camptothecin and layered double hydroxide. *Journal of Solid State Chemistry*, 183(8), 1811–1816.
- Dorniani, D., Hussein, M. Z., Kura, A. U., Fakurazi, S., Shaari, A. H., and Ahmand, Z. (2013). Preparation and characterization of 6-mercaptopurine-coated magnetite nanoparticles as a drug delivery system. *Drug Design, Development and Therapy*, 7, 1015–1026.
- Dorniani, D., Hussein, M. Z., Kura, A. U., Fakurazi, S., Shaari, A. H., and Ahmand, Z. (2012). Preparation of Fe_3O_4 magnetic nanoparticles coated with gallic acid for drug delivery. *International Journal of Nanomedicine*, 7, 5745-5756.
- Dorniani, D., Kura, A. U., Hussein-Al-Ali, S. H., Hussein, M. Z., Fakurazi, S., Shaari, A. H., and Ahmad, Z. (2014a). *In vitro* sustained release study of gallic acid coated with magnetite-PEG and magnetite-PVA for drug delivery system. *The Scientific World Journal*, vol. 2014, Article ID 416354, 11 pages.
- Dresselhaus, M. S., Dresselhaus, G., Saito, R., and Jorio, A. (2005). Raman spectroscopy of carbon nanotubes. *Physics Reports*, 409(2), 47-99.
- Dresselhaus, M. S., Jorio, A., Hofmann, M., Dresselhaus, G., and Saito, R. (2010). Raman spectroscopy of graphene and carbon nanotubes. *Nano Letters*, 10(3), 751-758.
- Du, H. and Chen, X. (2009). CD-MEKC method to analyze triterpene acids in traditional Chinese medicines. *Journal of the Brazilian Chemical Society*, 20(7), 1268-1274.
- Dvash, R., Khatchatourians, A., Solmesky, L. J., Wibroe, P. P., Weil, M., Moghimi, S. M., and Peer, D. (2013). Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes. *Journal of Controlled Release*, 170(2), 295–305.
- Edwards, S. A. (2005). Nanobiomedical technology: financial, legal, clinical, political, ethical and societal challenges to implementation. In Kumar, C. S., Hormes, J., and Leuschner, C. *Nanofabrication Towards Biomedical Applications* (pp. 289-326). Weinheim: Wiley-VCH Verlag GmbH & Co.
- Elmowafy, M., Viitala, T., Ibrahim, H. M., Abu-Elyazid, S. A., Samy, A., Kassem, A., and Yliperttula, M. (2013). Silymarin loaded liposomes for hepatic targeting: *in vitro* evaluation and HepG2 drug uptake. *European Journal of Pharmaceutical Sciences*, 50(2), 161-171.
- Elsabahy, M., Nazarali, A., and Foldvari, M. (2011). Non-viral nucleic acid delivery: key challenges and future directions. *Current Drug Delivery*, 8(3), 235-244.
- El-Samaligy, M. S., Afifi, N. N., and Mahmoud, E. A. (2006). Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. *International Journal of Pharmaceutics*, 308(1-2), 140–148.

- El-Sherbiny, I. M., Abdel-Mogib, M., Dawidar, A. A. M., Elsayed, A., and Smyth, H. D. C. (2011). Biodegradable pH-responsive alginate-poly (lactic-co-glycolic acid) nano/micro hydrogel matrices for oral delivery of silymarin. *Carbohydrate Polymers*, 83(3), 1345–1354.
- Englyst, H. N., Hay, S., and Macfarlane, G. T. (1987). Polysaccharide breakdown by mixed populations of human faecal bacteria. *FEMS Microbiology Letters*, 45(3), 163-171.
- Ergün, Y., Kurutas, E. B., Atalay, F., and Alici, T. (2013). Effects of silibinin and ethanol on skeletal muscle ischemia-reperfusion injury. *Acta Cirurgica Brasileira*, 28(3), 179-184.
- Evans, D. F., Bramley, G. P., Clark, A. G., Dyson, T. J., and Hardcastle, J. D. (1988). Measurement of gastrointestinal pH profiles in normal ambulant human subjects. *Gut*, 29(8), 1035-1041.
- Fan, J., Zeng, F., Xu, J., and Wu, S. (2013). Targeted anti-cancer prodrug based on carbon nanotube with photodynamic therapeutic effect and pH-triggered drug release. *Journal of Nanoparticle Research*, 15(9), Article 1911.
- Fang, J. Y., Lee, W. R., Shen, S. C., Wang, H. Y., Fang, C. L., and Hu, C. H. (2004). Transdermal delivery of macromolecules by erbium: YAG laser. *Journal of Controlled Release*, 100(1), 75-85.
- Farokhzad, O. C. and Langer, R. (2009). Impact of nanotechnology on drug delivery. *ACS Nano*, 3(1), 16-20.
- Federsel, H. J. (2009). Chemical process research and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective. *Accounts of Chemical Research*, 42(5), 671-680.
- Feng, W. and Ji, P. (2011). Enzymes immobilized on carbon nanotubes. *Biotechnology Advances*, 29(6), 889–895.
- Fernando, K. A. S., Lin, Y., Wang, W., Kumar, S., Zhou, B., Xie, S. Y., Cureton, L. T., and Sun, Y. P. (2004). Diminished band-gap transitions of single-walled carbon nanotubes in complexation with aromatic molecules. *Journal of the American Chemical Society*, 126(33), 10234–10235.
- Filip, J., Šefčovičová, J., Tomčík, P., Gemeiner, P., and Tkac, J. (2011). A hyaluronic acid dispersed carbon nanotube electrode used for a mediatorless NADH sensing and biosensing. *Talanta*, 84(2), 355–361.
- Firme III, C. P. and Bandaru, P. R. (2010). Toxicity issues in the application of carbon nanotubes to biological systems. *Nanomedicine*, 6(2), 245–256.
- Foldvari, M. and Bagonluri, M. (2008). Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. *Nanomedicine*, 4(3), 183–200.

- Fraczek-Szczypta, A., Menaszek, E., and Blazewicz, S. (2011). Some observations on carbon nanotubes susceptibility to cell phagocytosis. *Journal of Nanomaterials*, vol. 2011, Article ID 473516, 8 pages.
- Frandsen, J. L. and Ghandehari, H. (2012). Recombinant protein-based polymers for advanced drug delivery. *Chemical Society Reviews*, 41(7), 2696-2706.
- Frantz, S. (2006). Pharma companies becoming more aggressive towards generics firms. *Nature Reviews Drug Discovery*, 5(8), 619-620.
- Freeman, H. S. and Mock, G. N. (2007). Dye application, manufacture of dye intermediates and dyes. In Kent, J. A. *Kent and Riegel's Handbook of Industrial Chemistry and Biotechnology* (pp. 499-590). New York: Springer Science+Business Media.
- Fruijtier-Pölloth, C. (2005). Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. *Toxicology*, 214(1-2), 1-38.
- Fu, T., Liu, R., Lv, J., and Li, Z. (2014). Influence of acid treatment on N-doped multi-walled carbon nanotube supports for Fischer-Tropsch performance on cobalt catalyst. *Fuel Processing Technology*, 122, 49-57,
- Gaillard, C., Duval, M., Dumortier, H., and Bianco, A. (2011). Carbon nanotube-coupled cell adhesion peptides are nonimmunogenic: a promising step toward new biomedical devices. *Journal of Peptide Science*, 17(2), 139–142.
- Gandhi, R. B. and Robinson, J. R. (1994). Oral cavity as a site for bioadhesive drug delivery. *Advanced Drug Delivery Reviews*, 13(1-2), 43-74.
- Gazak, R., Walterova, D., and Kren, V. (2007). Silybin and silymarin – new and emerging applications in medicine. *Current Medicinal Chemistry*, 14, 315-338.
- Ge, B., Tan, Y., Xie, Q., Ma, M., and Yao, S. (2009). Preparation of chitosan-dopamine-multiwalled carbon nanotubes nanocomposite for electrocatalytic oxidation and sensitive electroanalysis of NADH. *Sensors and Actuators B*, 137(2), 547-554.
- Ge, C., Du, J., Zhao, L., Wang, L., Liu, Y., Li, D., Yang, Y., Zhou, R., Zhao, Y., Chai, Z., and Chen, C. (2011a). Binding of blood proteins to carbon nanotubes reduces cytotoxicity. *Proceedings of the National Academy of Sciences of the United States of America*, 108(41), 16968–16973.
- Ge, Y., Zhang, Y., Chen, Y., Li, Q., Chen, J., Dong, Y., and Shi, W. (2011b). Silibinin causes apoptosis and cell cycle arrest in some human pancreatic cancer cells. *International Journal of Molecular Sciences*, 12, 4861-4871.
- Ghaffarian, R., Bhowmick, T., and Muro, S. (2012). Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1. *Journal of Controlled Release*, 163(1), 25–33.

- Ghini, G., Trono, C., Giannetti, A., Puleo, G. L., Luconi, L., Amadou, J., Giambastiani, G., and Baldini, F. (2013). Carbon nanotubes modified with fluorescein derivatives for pH nanosensing. *Sensors and Actuators B*, 179, 163–169.
- Gill, H. S. and Prausnitz, M. R. (2007). Coated microneedles for transdermal delivery. *Journal of Controlled Release*, 117(2), 227-237.
- Goldman, J. G. and Goetz, C. G. (2007). History of Parkinson's disease. *Handbook of Clinical Neurology*, 83, 107-128.
- Gotovac, S., Song, L., Kanoh, H., and Kaneko, K. (2007). Assembly structure control of single wall carbon nanotubes with liquid phase naphthalene adsorption. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, 300(1-2), 117–121.
- Grandi, S., Magistris, A., Mustarelli, P., Quartarone, E., Tomasi, C., and Meda, L. (2006). Synthesis and characterization of SiO-PEG hybrid materials. *Journal of Non-Crystalline Solids*, 352(3), 273–280.
- Griffiths, J. R. (1991). Are cancer cells acidic? *British Journal of Cancer*, 64(3), 425–427.
- Griffiths, J. R., McIntyre, D. J., Howe, F. A., and Stubbs, M. (2001). Why are cancers acidic? A carrier-mediated diffusion model for H⁺ transport in the interstitial fluid. *Novartis Foundation Symposia*, 240, 46–62.
- Guo, Z., Xiong, J., Yang, M., Xiong, S., Chen, J., Wu, Y., Fan, H., Sun, L., Wang, J., and Wang, H. (2010). Dispersion of nano-TiN powder in aqueous media. *Journal of Alloys and Compounds*, 493(1-2), 362-367.
- Hadidi, N., Kobarfard, F., Nafissi-Varcheh, N., and Aboofazeli, R. (2011). Optimization of single-walled carbon nanotube solubility by noncovalent PEGylation using experimental design methods. *International Journal of Nanomedicine*, 6, 737–746.
- Halpern, D., Fujioka, H., Takayama, S., and Grotberg, J. B. (2008). Liquid and surfactant delivery into pulmonary airways. *Respiratory Physiology & Neurobiology*, 163(1-3), 222-231.
- Hao, Y., Xu, P., He, C., Yang, X., Huang, M., Xing, J., and Chen, J. (2011). Impact of carbodiimide crosslinker used for magnetic carbon nanotube mediated GFP plasmid delivery. *Nanotechnology*, 22(28), 1–9.
- Hariharan, R., Senthilkumar, S., Suganthi, A., and Rajarajan, M. (2012). Synthesis and characterization of doxorubicin modified ZnO/PEG nanomaterials and its photodynamic action. *Journal of Photochemistry and Photobiology B: Biology*, 116, 56–65.
- Hatefi, A. and Amsden, B. (2002). Biodegradable injectable *in situ* forming drug delivery systems. *Journal of Controlled Release*, 80(1-3), 9-28.

- Hearnden, V., Sankar, V., Hull, K., Juras, D. V., Greenberg, M., Kerr, A. R., Lockhart, P. B., Patton, L. L., Porter, S., and Thornhill, M. H. (2012). New developments and opportunities in oral mucosal drug delivery for local and systemic disease. *Advanced Drug Delivery Reviews*, 64(1), 16-28.
- Heister, E., Neves, V., Lamprecht, C., Silva, S. R. P., Coley, H. M., and McFadden, J. (2012). Drug loading, dispersion stability, and therapeutic efficacy in targeted drug delivery with carbon nanotubes. *Carbon*, 50(2), 622–632.
- Heister, E., Neves, V., Tilmaciuc, C., Lipert, K., Beltran, V. S., Coley, H. M., Silva, S. R. P., and McFadden, J. (2009). Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy. *Carbon*, 47(9), 2152–2160.
- Henry, S., McAllister, D. V., Allen, M. G., and Prausnitz, M. R. (1998). Microfabricated microneedles: a novel approach to transdermal drug delivery. *Journal of Pharmaceutical Sciences*, 87(8), 922-925.
- Herold, D. A., Rodeheaver, G. T., Bellamy, W. T., Fitton, L. A., Bruns, D. E., and Edlich, R. F. (1982). Toxicity of topical polyethylene glycol. *Toxicology and Applied Pharmacology*, 65(2), 329-335.
- Hilding, J. M. and Grulke, E. A. (2004). Heat of adsorption of butane on multiwalled carbon nanotubes. *The Journal of Physical Chemistry B*, 108(36), 13688–13695.
- Hiorth, M., Skøien, T., and Sande, S. A. (2010). Immersion coating of pellet cores consisting of chitosan and calcium intended for colon drug delivery. *European Journal of Pharmaceutics and Biopharmaceutics*, 75(2), 245-253.
- Hirsch, A. (2002). Funktionalisierung von einwandigen Kohlenstoff-nanoröhren. *Angewandte Chemie*, 114, 1933–1939.
- Ho, Y. S. and Ofomaja, A. E. (2006). Pseudo-second-order model for lead ion sorption from aqueous solutions onto palm kernel fiber. *Journal of Hazardous Materials*, 129(1–3), 137–142.
- Hofer, M., Winter, G., and Myschik, J. (2012). Recombinant spider silk particles for controlled delivery of protein drugs. *Biomaterials*, 33(5), 1554–1562.
- Hoh, C. S., Boocock, D. J., Marczylo, T. H., Brown, V. A., Cai, H., Steward, W. P., Berry, D. P., and Gescher, A. J. (2007). Quantitation of silibinin, a putative cancer chemopreventive agent derived from milk thistle (*Silybum marianum*), in human plasma by high-performance liquid chromatography and identification of possible metabolites. *Journal of Agricultural and Food Chemistry*, 55(7), 2532-2535.
- Hou, P., Liu, C., Tong, Y., Xu, S., Liu, M., and Cheng, H. (2001). Purification of single-walled carbon nanotubes synthesized by the hydrogen arc-discharge method. *Journal of Materials Research*, 16(9), 2526–2529.

- Hruby, K., Csomas, G., Fuhrmann, M., and Thaler, H. (1983). Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. *Human & Experimental Toxicology*, 2(2), 183-195.
- Hu, L., Batheja, P., Meidan, V., and Michniak-Kohn, B. B. (2010). Iontophoretic transdermal drug delivery. In Kulkarni, V. S. *Handbook of Non-Invasive Drug Delivery Systems* (pp. 95-118). United States of America: Elsevier Inc.
- Hu, Q., Yu, J., Liu, M., Liu, A., Dou, Z., and Yang, Y. (2014a). A low cytotoxic cationic metal-organic framework carrier for controllable drug release. *Journal of Medicinal Chemistry*, 57(13), 5679-5685.
- Hu, X., Wang, Y., and Peng, B. (2014b). Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release. *Chemistry - An Asian Journal*, 9(1), 319-327.
- Hu, Z., Prasad, Y. R., Tawa, R., Konishi, T., Ishida, M., Shibata, N., and Takada, K. (2002). Diethyl ether fraction of Labrasol having a stronger adsorption enhancing effect on gentamicin than Labrasol itself. *International Journal of Pharmaceutics*, 234(1-2), 223-235.
- Huang, H., Yuan, Q., Shah, J. S., and Misra, R. D. K. (2011a). A new family of folate-decorated and carbon nanotube-mediated drug delivery system: synthesis and drug delivery response. *Advanced Drug Delivery Reviews*, 63(14-15), 1332-1339.
- Huang, L., Wu, B., Chen, J., Xue, Y., Liu, Y., Kajiura, H., and Li, Y. (2011b). Synthesis of single-walled carbon nanotubes by an arc-discharge method using selenium as a promoter. *Carbon*, 49(14), 4792-4800.
- Huang, X. and Brazel, C. S. (2001). On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. *Journal of Controlled Release*, 73(2-3), 121-136.
- Hughes, G. A. (2005). Nanostructure-mediated drug delivery. *Nanomedicine: Nanotechnology, Biology, and Medicine*, 1(1), 22-30.
- Hussain, A., Arnold, J. J., Khan, M. A., and Ahsan, F. (2004). Absorption enhancers in pulmonary protein delivery. *Journal of Controlled Release*, 94(1), 15-24.
- Hussain, S., Jha, P., Chouksey, A., Raman, R., Islam, S. S., Islam, T., and Choudhary, P. K. (2011). Spectroscopic investigation of modified single wall carbon nanotube (SWCNT). *Journal of Modern Physics*, 2(6), 538-543.
- Hussein-Al-Ali, S. H., Al-Qubaisi, M., Hussein, M. Z., Ismail, M., Zainal, Z., and Hakim, M. N. (2012). *In vitro* inhibition of histamine release behavior of cetirizine intercalated into Zn/Al- and Mg/Al-layered double hydroxides. *International Journal of Molecular Sciences*, 13(5), 5899-5916.

- Hussein-Al-Ali, S. H., Arulselvan, P., Fakurazi, S., and Hussein, M. Z. (2014). The *in vitro* therapeutic activity of betulinic acid nanocomposite on breast cancer cells (MCF-7) and normal fibroblast cell (3T3). *Journal of Materials Science*, 49(23), 8171-8182.
- Iijima, S. (1991). Helical microtubules of graphitic carbon. *Nature*, 354, 56–58.
- Iijima, S. (2002). Carbon nanotubes: past, present, and future. *Physica B: Condensed Matter*, 323(1–4), 1–5.
- Iijima, S. and Ichihashi, T. (1993). Single-shell carbon nanotubes of 1nm diameter. *Nature*, 363(6430), 603–605.
- Ilbasmis-Tamer, S., Yilmaz, S., Banoğlu, E., and Değim, I. T. (2010). Carbon nanotubes to delivery drug molecules. *Journal of Biomedical Nanotechnology*, 6, 20–27.
- Illum, L. (2000). Transport of drugs from the nasal cavity to the central nervous system. *European Journal of Pharmaceutical Sciences*, 11(1), 1-18.
- Inoue, N., Kobayashi, D., Kimura, M., Toyama, M., Sugawara, I., Itoyama, S., Ogihara, M., Sugabayashi, K., and Morimoto, Y. (1996). Fundamental investigation of a novel drug delivery system, a transdermal delivery system with jet injection. *International Journal of Pharmaceutics*, 137(1), 75-84.
- Itkis, M. E., Perea, D. E., Jung, R., Niyogi, S., and Haddon, R. C. (2005). Comparison of analytical techniques for purity evaluation of single-walled carbon nanotubes. *Journal of the American Chemical Society*, 127(10), 3439–3448.
- Jain, A. K., Dubey, V., Mehra, N. K., Lodhi, N., Nahar, M., Mishra, D. K., and Jain, N. K. (2009). Carbohydrate-conjugated multiwalled carbon nanotubes: development and characterization. *Nanomedicine: Nanotechnology, Biology and Medicine*, 5(4), 432–442.
- Jain, K. K. (2008). Drug delivery systems – an overview. In Jain, K. K. *Methods in Molecular Biology*, Vol. 437: *Drug Delivery Systems* (pp.1-50). Totowa: Humana Press.
- Jain, M., Kapadia, R., Jadeja, R. N., Thounaojam, M. C., Devkar, R. V., and Mishra, S. H. (2012). Hepatoprotective potential of *Tecomella undulata* stem bark is partially due to the presence of betulinic acid. *Journal of Ethnopharmacology*, 143(1), 194–200.
- Jakki, R., Afzal Syed, M., Kandadi, P., and Veerabrahma, K. (2013). Development of a self-microemulsifying drug delivery system of domperidone: *in vitro* and *in vivo* characterization. *Acta Pharmaceutica*, 63(2), 241-251.
- Ji, Z., Lin, G., Lu, Q., Meng, L., Shen, X., Dong, L., Fu, C., and Zhang, X. (2012). Targeted therapy of SMMC-7721 liver cancer *in vitro* and *in vivo* with carbon nanotubes based drug delivery system. *Journal of Colloid and Interface Science*, 365(1), 143–149.

- Johnson Jr., C. S. (1999). Diffusion ordered nuclear magnetic resonance spectroscopy: principles and applications. *Progress in Nuclear Magnetic Resonance Spectroscopy*, 34(3-4), 203–256.
- Jos, A., Pichardo, S., Puerto, M., Sánchez, E., Grilo, A., and Cameán, A. M. (2009). Cytotoxicity of carboxylic acid functionalized single wall carbon nanotubes on the human intestinal cell line Caco2. *Toxicology in Vitro*, 23(8), 1491–1496.
- Joshi, M. D. and Müller, R. H. (2009) Lipid nanoparticles for parenteral delivery of actives. *European Journal of Pharmaceutics and Biopharmaceutics*, 71(2), 161–172.
- Jung, G. R., Kim, K. J., Choi, C. H., Lee, T. B., Han, S. I., Han, H. K., and Lim, S. C. (2007). Effect of betulinic acid on anticancer drug-resistant colon cancer cells. *Basic & Clinical Pharmacology & Toxicology*, 101(4), 277–285.
- Jung, Y., Song, J., Huh, W., Cho, D., and Jeong, Y. (2013). Controlling the crystalline quality of carbon nanotubes with processing parameters from chemical vapor deposition synthesis. *Chemical Engineering Journal*, 228, 1050–1056.
- Kadajji, V. G. and Betageri, G. V. (2011). Water soluble polymers for pharmaceutical applications. *Polymers*, 3(4), 1972–2009.
- Kaiser, J. P., Roesslein, M., Buerki-Thurnherr, T., and Wick, P. (2011). Carbon nanotubes—curse or blessing. *Current Medicinal Chemistry*, 18(14), 2115–2128.
- Kajita, M., Morishita, M., Takayama, K., Chiba, Y., Tokiwa, S., and Nagai, T. (2000). Enhanced enteral bioavailability of vancomycin using water-in-oil-in-water multiple emulsion incorporating highly purified unsaturated fatty acid. *Journal of Pharmaceutical Sciences*, 89(10), 1243–1252.
- Kalbac, M., Hsieh, Y. P., Farhat, H., Kavan, L., Hofmann, M., Kong, J., and Dresselhaus, M. S. (2010). Defects in individual semiconducting single wall carbon nanotubes: Raman spectroscopic and *in situ* Raman spectroelectrochemical study. *Nano Letters*, 10(11), 4619–4626.
- Kang, M. L., Cho, C. S., and Yoo, H. S. (2009). Application of chitosan microspheres for nasal delivery of vaccines. *Biotechnology Advances*, 27(6), 857–865.
- Karande, P. and Mitragotri, S. (2009). Enhancement of transdermal drug delivery via synergistic action of chemicals. *Biochimica et Biophysica Acta - Biomembranes*, 1788(11), 2362–2373.
- Karchemski, F., Zucker, D., Barenholz, Y., and Regev, O. (2012). Carbon nanotubes-liposomes conjugate as a platform for drug delivery into cells. *Journal of Controlled Release*, 160(2), 339–345.
- Karim, B. O., Rhee, K. J., Liu, G., Zheng, D., and Huso, D. L. (2013). Chemoprevention utility of silibinin and Cdk4 pathway inhibition in *Apc*^{-/+} mice. *BMC Cancer*, 13, 157.

- Karousis, N. and Tagmatarchis, N. (2010). Current progress on the chemical modification of carbon nanotubes. *Chemical Reviews*, 110(9), 5366–5397.
- Katsuma, M., Watanabe, S., Takemura, S., Sako, K., Sawada, T., Masuda, Y., Nakamura, K., Fukui, M., Connor, A. L., and Wilding, I. R. (2004). Scintigraphic evaluation of a novel colon-targeted delivery system (CODES) in healthy volunteers. *Journal of Pharmaceutical Sciences*, 93(5), 1287-1299.
- Kaur, A. and Kaur, G. (2012). Mucoadhesive buccal patches based on interpolymer complexes of chitosan-pectin for delivery of carvedilol. *Saudi Pharmaceutical Journal*, 20(1), 21-27.
- Kaur, P., Shin, M. S., Joshi, A., Kaur, N., Sharma, N., Park, J. S., and Sekhon, S. S. (2013). Interactions between multiwall carbon nanotubes and poly(diallyldimethylammonium) chloride: effect of the presence of a surfactant. *Journal of Physical Chemistry B*, 117(11), 3161-3166.
- Kerwin, B. A. (2008). Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. *Journal of Pharmaceutical Sciences*, 97(8), 2924-2935.
- Kim, J., Cote, L. J., Kim, F., Yuan, W., Shull, K. R., and Huang, J. (2010). Graphene oxide sheets at interfaces. *Journal of the American Chemical Society*, 132(23), 8180–8186.
- Kim, S. W., Kim, T., Kim, Y. S., Choi, H. S., Lim, H. J., Yang, S. J., and Park, C. R. (2012). Surface modifications for the effective dispersion of carbon nanotubes in solvents and polymers. *Carbon*, 50(1), 3–33.
- Kim, U. J., Furtado, C. A., Liu, X., Chen, G., and Eklund, P. C. (2005). Raman and IR spectroscopy of chemically processed single-walled carbon nanotubes. *Journal of the American Chemical Society*, 127(44), 15437-15445.
- Kishinevsky, S., Nikitenko, S. I., Pickup, D. M., Van-Eck, E. R. H., and Gedanken, A. (2002). Catalytic transformation of carbon black to carbon nanotubes. *Chemistry of Materials*, 14(11), 4498–4501.
- Kissel, T., Brich, Z., Bantle, S., Lancranjan, I., Nimmerfall, F., and Vit, P. (1991). Parenteral depot-systems on the basis of biodegradable polyesters. *Journal of Controlled Release*, 16(1-2), 27-42.
- Klumpp, C., Kostarelos, K., Prato, M., and Bianco, A. (2006). Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. *Biochimica et Biophysica Acta - Biomembranes*, 1758(3), 404-412.
- Knop, K., Hoogenboom, R., Fischer, D., and Schubert, U. S. (2010). Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. *Angewandte Chemie International Edition*, 49(36), 6288-6308.

- Kommera, H., Kaluderović, G. N., Dittrich, S., Kalbitz, J., Dräger, B., Mueller, T., and Paschke, R. (2010). Carbamate derivatives of betulinic acid and betulin with selective cytotoxic activity. *Bioorganic and Medicinal Chemistry Letters*, 20(11), 3409–3412.
- Kong, Z., Yu, M., Cheng, K., Weng, W., Wang, H., Lin, J., Du, P., and Han, G. (2013). Incorporation of chitosan nanospheres into thin mineralized collagen coatings for improving the antibacterial effect. *Colloids Surface B Biointerfaces*, 111, 536-541.
- Kopeček, J., Kopečková, P., Brøndsted, H., Rathi, R., Říhová, B., Yeh, P. Y., and Ikesue, K. (1992). Polymers for colon-specific drug delivery. *Journal of Controlled Release*, 19(1-3), 121-130.
- Kostarelos, K., Lacerda, L., Pastorin, G., Wu, W., Wieckowski, S., Luangsivilay, J., Godefroy, S., Pantarotto, D., Briand, J. P., Muller, S., Prato, M., and Bianco, A. (2007). Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. *Nature Nanotechnology*, 2(2), 108–113.
- Koyama, S., Kim, Y. A., Hayashi, T., Takeuchi, K., Fujii, C., Kuroiwa, N., Koyama, H., Tsukahara, T., and Endo, M. (2009). *In vivo* immunological toxicity in mice of carbon nanotubes with impurities. *Carbon*, 47(5), 1365–1372.
- Kranz, H. and Bodmeier, R. (2007). A novel *in situ* forming drug delivery system for controlled parenteral drug delivery. *International Journal of Pharmaceutics*, 332(1-2), 107-114.
- Kura, A. U., Ain, N. M., Hussein, M. Z., Fakurazi, S., and Hussein-Al-Ali, S. H. (2014a). Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson's disease model. *International Journal of Molecular Science*, 15(4), 5916-5927.
- Kura, A. U., Hussein-Al-Ali, S. H., Hussein, M. Z., and Fakurazi, S. (2014b). Preparation of tween 80-zn/zl-levodopa-layered double hydroxides nanocomposite for drug delivery system. *The Scientific World Journal*, vol. 2014, Article ID 104246, 10 pages.
- Kura, A. U., Hussein-Al-Ali, S. H., Hussein, M. Z., Fakurazi, S., and Arulselvan, P. (2013). Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. *International Journal of Nanomedicine*, 8, 1103–1110.
- Kvasnička, F., Bíba, B., Ševčík, R., Voldřich, M., and Krátká, J. (2003). Analysis of the active components of silymarin. *Journal of Chromatography A*, 990(1-2), 239–245.
- Lacerda, L., Bianco, A., Prato, M., and Kostarelos, K. (2006). Carbon nanotubes as nanomedicines: from toxicology to pharmacology. *Advanced Drug Delivery Reviews*, 58(14), 1460–1470.

- Laidler, P., Maslin, S. C., and Gilhome, R. W. (1985). What's new in osmosin and intestinal perforation? *Pathology, Research and Practice*, 180(1), 74-76.
- Lavon, I. and Kost, J. (2004). Ultrasound and transdermal drug delivery. *Drug Discovery Today*, 9(15), 670-676.
- Lee, J., Oh, Y. J., Lee, S. K., and Lee, K. Y. (2010). Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery. *Journal of Controlled Release*, 146(1), 61-67.
- Lee, K., Lee, C. Y., and Jung, H. (2011). Dissolving microneedles for transdermal drug administration prepared by stepwise controlled drawing of maltose. *Biomaterials*, 32(11), 3134-3140.
- Lee, P., Chiou, Y., Wong, J., Peng, C., and Shieh, M. (2013). Targeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibody. *Biomaterials*, 34(34), 8756-8765.
- Lei, X. W., Ni, Q. Q., Shi, J. X., and Natsuki, T. (2011). Radial breathing mode of carbon nanotubes subjected to axial pressure. *Nanoscale Research Letters*, 6, 492-497.
- Leonard, A. K., Sileno, A. P., Brandt, G. C., Foerder, C. A., Quay, S. C., and Constantino, H. R. (2007). *In vitro* formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response *in vivo*. *International Journal of Pharmaceutics*, 335(1-2), 138-146.
- Leopold, C. S. (1999). Coated dosage forms for colon-specific drug delivery. *Pharmaceutical Science & Technology Today*, 2(5), 197-204.
- LeWitt, P. A. (2009). Levodopa therapeutics for Parkinson's disease: new developments. *Parkinsonism Relat Disord*, 15(1), S31-S34.
- Li, C., Yang, K., Zhang, Y., Tang, H., Yan, F., Tan, Liang, Xie, Q., and Yao, S. (2011a). Highly biocompatible multiwalled carbon nanotube-chitosan nanoparticle hybrids as protein carriers. *Acta Biomaterialia*, 7(8), 3070-3077.
- Li, F., Ma, Z., Guan, Z., Chen, Y., Wu, K., Guo, P., Wang, X., He, D., and Zeng, J. (2015). Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma. *International Journal of Molecular Science*;16, 8415-8429.
- Li, H. L., Zhao, X. B., Ma, Y. K., Zhai, G. X., Li, L. B., and Lou, H. X. (2009). Enhancements of gastrointestinal absorption of quercetin by solid lipid nanoparticles. *Journal of Controlled Release*, 133(3), 238-244.
- Li, R., Wu, R., Zhao, L., Hu, Z., Guo, S., Pan, X., and Zou, H. (2011b). Folate and iron difunctionalized multiwall carbon nanotubes as dual-targeted drug nanocarrier to cancer cells. *Carbon*, 49(5), 1797-1805.

- Li, Y., Wang, T., Wang, J., Jiang, T., Cheng, G., and Wang, S. (2011c). Functional and unmodified MWNTs for delivery of the water-insoluble drug Carvedilol—a drug-loading mechanism. *Applied Surface Science*, 257(13), 5663–5670.
- Lin, C. M., Chen, Y. H., Ma, H. P., Wang, B. W., Chiu, J. H., Chua, S. K., Ong, J. R., and Shyu, K. G. (2012). Silibinin inhibits the invasion of IL-6-stimulated colon cancer cells via selective JNK/AP-1/MMP-2 modulation *in vitro*. *Journal of Agricultural and Food Chemistry*, 60(51), 12451–12457.
- Lin, H., Lagoute, J., Repain, V., Chacon, C., Girard, Y., Lauret, J. S., Arenal, R., Ducastelle, F., Rousset, S., and Loiseau, A. (2011). Coupled study by TEM/EELS and STM/STS of electronic properties of C- and CN \times -nanotubes. *Comptes Rendus Physique*, 12(9-10), 909–920.
- Ling, X., Wei, Y., Zou, L., and Xu, S. (2014). Functionalization and dispersion of multiwalled carbon nanotubes modified with poly-L-lysine. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, 443, 19–26.
- Lippens, B. C. and de Boer, J. H. (1965). Studies on pore systems in catalysts: v. The t method. *Journal of Catalysis*, 4(3), 319–323.
- Liu, A. H., Honma, I., and Zhou, H. S. (2005). Electrochemical biosensor based on protein-polysaccharide hybrid for selective detection of nanomolar dopamine metabolite of 3,4-dihydroxyphenylacetic acid (DOPAC). *Eletrochimistry Communications*, 7(2), 233–236.
- Liu, J., Rinzler, A. G., Dai, H., Hafner, J. H., Bradley, R. K., Boul, P. J., Lu, A., Iverson, T., Shelimov, K., Huffman, C. B., Rodriguez-Macias, F., Shon, Y. S., Lee, T. R., Colbert, D. T., and Smalley, R. E. (1998). Fullerene pipes. *Science*, 280(5367), 1253–1256.
- Liu, L., Qin, Y., Guo, Z. X., and Zhu, D. (2003). Reduction of solubilized multi-walled carbon nanotubes. *Carbon*, 41(2), 331–335.
- Liu, X., Tao, H., Yang, K., Zhang, S., Lee, S. T., and Liu, Z. (2011). Optimization of surface chemistry on single-walled carbon nanotubes for *in vivo* photothermal ablation of tumors. *Biomaterials*, 32(1), 144–151.
- Liu, Y., Shi, K., and Zhitomirsky, I. (2014). New colloidal route for electrostatic assembly of oxide nanoparticle—carbon nanotube composites. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, 446, 15–22.
- Liu, Z., Chen, K., Davis, C., Sherlock, S., Cao, Q., Chen, X., and Dai, H. (2008). Drug delivery with carbon nanotubes for *in vivo* cancer treatment. *Cancer Research*, 68(16), 6652–6660.
- Liu, Z., Sun, X., Nakayama-Ratchford, N., and Dai, H. (2007). Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. *ACS Nano*, 1(1), 50–56.

- Liu, Z., Tabakman, S., Welsher, K., and Dai, H. (2009). Carbon nanotubes in biology and medicine: *in vitro* and *in vivo* detection, imaging and drug delivery. *Nano Research*, 2(2), 85-120.
- Lu, F., Gu, L., Meziani, M. J., Wang, X., Luo, P. G., Veca, L. M., Cao, L., and Sun, Y. P. (2009). Advances in bioapplications of carbon nanotubes. *Advanced Materials*, 21(2), 139–152.
- Lu, Y. J., Wei, K. C., Ma, C. C. M., Yang, S. Y., and Chen, J. P. (2012). Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. *Colloids and Surfaces B: Biointerfaces*, 89(1), 1–9.
- Luo, X., Matranga, C., Tan, S., Alba, N., and Cui, X. T. (2011). Carbon nanotube nanoreservoir for controlled release of anti-inflammatory dexamethasone. *Biomaterials*, 32(26), 6316– 6323.
- Lvovich, V. F., Matthews, E., Riga, A. T., and Kaza, L. (2010). AC electrokinetic platform for iontophoretic transdermal drug delivery. *Journal of Controlled Release*, 145(2), 134-140.
- Ma, Y., Li, W. Z., and Gu, J. H. (2011). Preparation and evaluation of the solid dispersions of poorly soluble silybin. *Journal of Chinese Pharmaceutical Sciences*, 20(6), 604–608.
- Madani, S. Y., Naderi, N., Dissanayake O, and Seifalian, A. M. (2011). A new era of cancer treatment: carbon nanotubes as drug delivery tools. *International Journal of Nanomedicine*, 6, 2963-2979.
- Madani, S. Y., Tan, A., Dwek, M., and Seifalian, A. M. (2012). Functionalization of single-walled carbon nanotubes and their binding to cancer cells. *International Journal of Nanomedicine*, 7, 905-914.
- Madhav, N. V., Shakya, A. K., Shakya, P., and Singh, K. (2009). Orotransmucosal drug delivery systems: a review. *Journal of Controlled Release*, 140(1), 2-11.
- Magliulo, E., Gagliardi, B., and Fiori, G. P. (1978). Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. *Medizinische Klinik*, 73(28-29), 1060-1065.
- Magrez, A., Kasas, S., Salicio, V., Pasquier, N., Seo, J. W., Celio, M., Catsicas, S., Schwaller, B., and Forró, L. (2006). Cellular toxicity of carbon-based nanomaterials. *Nano Letters*, 6(6), 1121–1125.
- Malaterre, V., Ogorka, J., Loggia, N., and Gurny, R. (2009). Oral osmotically driven systems: 30 years of development and clinical use. *European Journal of Pharmaceutics and Biopharmaceutics*, 73(3), 311-323.
- Marianecci, C., Paolino, D., Celia, C., Fresta, M., Carafa, M., and Alhaique, F. (2010). Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts. *Journal of Controlled Release*, 147(1), 127-135.

- Martin, D., Weise, A., and Niclas, H. J. (1967). The solvent dimethyl sulfoxide. *Angewandte Chemie International Edition in English*, 6(4), 318-334.
- Martin, L., Wilson, C. G., Koosha, F., and Uchegbu, I. F. (2003). Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol chitosan hydrogels. *European Journal of Pharmaceutics and Biopharmaceutics*, 55(1), 35-45.
- Marques, R. R. N., Machado, B. F., Faria, J. L., and Silva, A. M. T. (2010). Controlled generation of oxygen functionalities on the surface of single-walled carbon nanotubes by HNO_3 hydrothermal oxidation. *Carbon*, 48(5), 1515–1523.
- McDevitt, M. R., Chattopadhyay, D., Kappel, B. J., Jaggi, J. S., Schiffman, S. R., Antczak, C., Njardarson, J. T., Brentjens, R., and Scheinberg, D. A. (2007). Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. *Journal of Nuclear Medicine*, 48(7), 1180–1189.
- Mehra, N. K. and Jain, N. K. (2013). Development, characterization and cancer targeting potential of surface engineered carbon nanotubes. *Journal of Drug Targeting*, 21(8), 745–758.
- Mehra, N. K., Verma, A. K., Mishra, P. R., and Jain N. K. (2014). The cancer targeting potential of D- α -tocopheryl polyethylene glycol 1000 succinate tethered multi walled carbon nanotubes. *Biomaterials*, 35(15), 4573–4588.
- Mehta, R. C., Thanoo, B. C., and DeLuca, P. P. (1996). Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide). *Journal of Controlled Release*, 41(3), 249-257.
- Ménard-Moyon, C., Kostarelos, K., Prato, M., and Bianco, A. (2010). Functionalized carbon nanotubes for probing and modulating molecular functions. *Chemistry & Biology*, 17(2), 107–115.
- Meng, L., Jiang, A., Chen, R., Li, C. Z., Wang, L., Qu, Y., Wang, P., Zhao, Y., and Chen, C. (2012). Inhibitory effects of multiwall carbon nanotubes with high iron impurity on viability and neuronal differentiation in cultured PC12 cells. *Toxicology*, 313(1), 49–58.
- Mi, H., Zhang, X., Xu, Y., and Xiao, F. (2010). Synthesis, characterization and electrochemical behavior of polypyrrole/carbon nanotube composites using organometallic-functionalized carbon nanotubes. *Applied Surface Science*, 256(7), 2284–2288.
- Minati, L., Speranza, G., Bernagozzi, I., Torrengo, S., Chiasera, A., and Ferrari, M. (2011). Luminescent short thiol-functionalized multiwall carbon nanotubes. *Diamond and Related Materials*, 20(7), 1046–1049.
- Minko, T. (2004). Drug targeting to the colon with lectins and neoglycoconjugates. *Advanced Drug Delivery Reviews*, 56(4), 491-509.

- Mitragotri, S. (2004). Sonophoresis: a 50-year journey. *Drug Discovery Today*, 9(17), 735-736.
- Miyata, Y., Mizuno, K., and Kataura, H. (2011). Purity and defect characterization of single-wall carbon nanotubes using Raman spectroscopy. *Journal of Nanomaterials*, vol. 2011, Article ID 786763, 7 pages.
- Modi, C. D., Patel, S. J., Desai, A. B., and Murthy, R. S. R. (2011). Functionalization and evaluation of PEGylated carbon nanotubes as novel drug delivery for methotrexate. *Journal of Applied Pharmaceutical Science*, 1(5), 103–108.
- Modi, G., Pillay, V., Choonara, Y. E., Ndescendo, V. M. K., Du Toit, L. C., and Naidoo, D. (2009). Advances in the treatment of Parkinson's disease. *Progress in Neurobiology*, 88(4), 272-285.
- Morales, J. O. and McConvile, J. T. (2011). Manufacture and characterization of mucoadhesive buccal films. *European Journal of Pharmaceutics and Biopharmaceutics*, 77(2), 187-199.
- Morimoto, K., Uehara, Y., Iwanaga, K., and Kakemi, M. (2000). Effects of sodium glycocholate and protease inhibitors on permeability of TRH and insulin across rabbit trachea. *Pharmaceutica Acta Helvetiae*, 74(4), 411-415.
- Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *Journal of Immunological Methods*, 65(1-2), 55–63.
- Mrsny, R. J. (1992). The colon as a site for drug delivery. *Journal of Controlled Release*, 22, 15-34.
- Muraoka, M., Hu, Z., Shimokawa, T., Sekino, S., Kurogoshi, R., Kuboi, Y., Yoshikawa, Y., and Takada, K. (1998). Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. *Journal of Controlled Release*, 52(1-2), 119-129.
- Murthy, S. N., Sammeta, S. M., and Bowers, C. (2010). Magnetophoresis for enhancing transdermal drug delivery: mechanistic studies and patch design. *Journal of Controlled Release*, 148(2), 197-203.
- Muthukumar, T., Prabhavathi, S., Chamundeeswari, M., and Sastry, T. P. (2014). Bio-modified carbon nanoparticles loaded with methotrexate possible carrier for anticancer drug delivery. *Materials Science and Engineering C*, 36(1), 14–19.
- Muzzalupo, R., Tavano, L., Cassano, R., Trombino, S., Cilea, A., and Picci, N. (2010). Colon-specific devices based on methacrylic functionalized Tween monomer networks: swelling studies and *in vitro* drug release. *European Polymer Journal*, 46(2), 209-216.
- Mazzarelli, R., Baldassarre, V., Conti, F., Ferrara, P., Biagini, G., Gazzanelli, G., and Vasi, V. (1988). Biological activity of chitosan: ultrastructural study. *Biomaterials*, 9(3), 247-252.

- Mytilineou, C., Walker, R. H., JnoBaptiste, R., and Olanow, C. W. (2003). Levodopa is toxic to dopamine neurons in an *in vitro* but not an *in vivo* model of oxidative stress. *Journal of Pharmacology and Experimental Therapeutics*, 304(2), 792-800.
- Nader, M. A. and Baraka, H. N. (2012). Effect of betulinic acid on neutrophil recruitment and inflammatory mediator expression in lipopolysaccharide-induced lung inflammation in rats. *European Journal of Pharmaceutical Sciences*, 46(1-2), 106–113.
- Nagendrappa, G. (2010). Sir William Henry Perkin: the man and his ‘mauve’. *Resonance*, 779-793.
- Narayananpillai, S., Agarwal, C., Deep, G., and Agarwal, R. (2014). Silibinin inhibits ultraviolet B radiation-induced DNA-damage and apoptosis by enhancing interleukin-12 expression in JB6 cells and SKH-1 hairless mouse skin. *Molecular Carcinogenesis*, 53, 471-479.
- Naik, A., Kalia, Y. N., and Guy, R. H. (2000). Transdermal drug delivery: overcoming the skin's barrier function. *Pharmaceutical Science & Technology Today*, 3(9), 318-326.
- Neelgund, G. M., Oki, A., and Luo, Z. (2012). Antimicrobial activity of CdS and Ag₂S quantum dots immobilized on poly(amidoamine) grafted carbon nanotubes. *Colloids and Surfaces B: Biointerfaces*, 100, 215–221.
- Nowacki, M., Wiśniewski, M., Werengowska-Ciećwierz, K., Terzyk, A. P., Kłoskowski, T., Marszałek, A., Bodnar, M., Pokrywczyńska, M., Nazarewski, Ł., Pietkun, K., Jundziłł, A., and Drewa, T. (2015). New application of carbon nanotubes in haemostatic dressing filled with anticancer substance. *Biomedicine & Pharmacotherapy*, 69, 349-354.
- Ntim, S. A., Sae-Khow, O., Witzmann, F. A., and Mitra, S. (2011). Effects of polymer wrapping and covalent functionalization on the stability of MWCNT in aqueous dispersions. *Journal of Colloid and Interface Science*, 355(2), 383–388.
- Ochekpe, N. A., Olorunfemi, P. O., and Ngwuluka, N. C. (2009). Nanotechnology and drug delivery part 1: background and applications. *Tropical Journal of Pharmaceutical Research*, 8(3), 265-274.
- O'Connell, M. J., Boul, P., Ericson, L. M., Huffman, C., Wang, Y., Haroz, E., Kuper, C., Tour, J., Ausman, K. D., and Smalley, R. E. (2001). Reversible water-solubilization of single-walled carbon nanotubes by polymer wrapping. *Chemical Physics Letters*, 342(3-4), 265-271.
- Ogura, M., Paliwal, S., and Mitragotri, S. (2008). Low-frequency sonophoresis: current status and future prospects. *Advanced Drug Delivery Reviews*, 60(10), 1218-1223.

- Okereke, C. S., Kirby, L., Kumar, D., Cullen, E. I., Pratt, R. D., and Hahne, W. A. (2004). Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. *British Journal of Clinical Pharmacology*, 58(1), 41-49.
- Oleszczuk, P. and Xing, B. (2011). Influence of anionic, cationic and nonionic surfactants on adsorption and desorption of oxytetracycline by ultrasonically treated and non-treated multiwalled carbon nanotubes. *Chemosphere*, 85(8), 1312–1317.
- Omar, S., Aldosari, B., Refai, H., and Gohary, O. A. (2007). Colon-specific drug delivery for mebeverine hydrochloride. *Journal of Drug Targeting*, 15(10), 691-700.
- Packhaeuser, C. B., Schnieders, J., Oster, C. G., and Kissel, T. (2004). *In situ* forming parenteral drug delivery systems: an overview. *European Journal of Pharmaceutics and Biopharmaceutics*, 58(2), 445-455.
- Page, D. T. and Cudmore, S. (2001). Innovations in oral gene delivery: challenges and potentials. *Drug Discovery Today*, 6(2), 92-101.
- Paiva, M. C., Xu, W., Proen  a, M. F., Novais, R. M., L  egsgaard, E., and Besenbacher, F. (2010). Unzipping of functionalized multiwall carbon nanotubes induced by STM. *Nano Letters*, 10(5), 1764–1768.
- Pantarotto, D., Partidos, C. D., Hoebelke, J., Brown, F., Kramer, E., Briand, J. P., Muller, S., Prato, M., and Bianco, A. (2003). Immunization with peptide-functionalized carbon nanotubes enhances virus specific neutralizing antibody responses. *Chemistry and Biology*, 10(10), 961–966.
- Pares, A., Planas, R., Torres, M., Caballeria, J., Viver, J. M., Acero, D., Panes, J., Rigau, J., Santos, J., and Rodes, J. (1998). Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. *Journal of Hepatology*, 28(4), 615-621.
- Park, J. H., Choi, S. O., Seo, S., and Choy, Y. B. (2010). A microneedle roller for transdermal drug delivery. *European Journal of Pharmaceutics and Biopharmaceutics*, 76(2), 282-289.
- Park, S., Shin, J., Lee, J., and Cha, M. (2012a). Manipulation of NIH3T3 cells with functionalized single-walled carbon nanotubes under a magnetic field. *Materials Letters*, 68, 378–381.
- Park, S. H., Kwon, J. H., Lim, S. H., Park, H. W., and Kim, C. W. (2007). Characterization of human insulin microcrystals and their absorption enhancement by protease inhibitors in rat lungs. *International Journal of Pharmaceutics*, 339(1-2), 205-212.

- Park, T. J., Kim, Y. S., Hwang, T., Govindaiah, P., Choi, S. W., Kim, E., Won, K., Lee, S. H., and Kim, J. H. (2012b). Preparation and characterization of heparinized multi-walled carbon nanotubes. *Process Biochemistry*, 47(1), 113–118.
- Patel, V. F., Liu, F., and Brown, M. B. (2011). Advances in oral transmucosal drug delivery. *Journal of Controlled Release*, 153(2), 106-116.
- Patlolla, A., Knighten, B., and Tchounwou, P. (2010). Multi-walled carbon nanotubes induce cytotoxicity, genotoxicity and apoptosis in normal human dermal fibroblast cells. *Ethnicity & Disease*, 20(1), S65–S72.
- Patočka, J. (2003). Biologically active pentacyclic triterpenes and their current medicine signification. *Journal of Applied Biomedicine*, 10(3), 7–12.
- Patton, J. S. (2000). Pulmonary delivery of drugs for bone disorders. *Advanced Drug Delivery Reviews*, 42(3), 239-248.
- Peng, H., Alemany, L. B., Margrave, J. L., and Khabashesku, V. N. (2003). Sidewall carboxylic acid functionalization of single-walled carbon nanotubes. *Journal of American Chemical Society*, 125(49), 15174-15182.
- Peretz, S. and Regev, O. (2012). Carbon nanotubes as nanocarriers in medicine. *Current Opinion in Colloid & Interface Science*, 17(6), 360–368.
- Perioli, L., Ambrogi, V., Angelici, F., Ricci, M., Giovagnoli, S., Capuccella, M., and Rossi, C. (2004). Development of mucoadhesive patches for buccal administration of ibuprofen. *Journal of Controlled Release*, 99(1), 73-82.
- Pillai, O., Dhanikula, A. B., and Panchagnula, R. (2001). Drug delivery: an odyssey of 100 years. *Current Opinion in Chemical Biology*, 5(4), 439-446.
- Pitarresi, G., Casadei, M. A., Mandracchia, D., Paolicelli, P., Palumbo, F. S., and Giammona, G. (2007). Photocrosslinking of dextran and polyaspartamide derivatives: a combination suitable for colon-specific drug delivery. *Journal of Controlled Release*, 119(3), 328-338.
- Plourde, F., Motulsky, A., Couffin-Hoarau, A. C., Hoarau, D., Ong, H., and Leroux, J. C. (2005). First report on the efficacy of L-alanine-based *in situ*-forming implants for the long-term parenteral delivery of drugs. *Journal of Controlled Release*, 108(2-3), 433-441.
- Podesta, J. E., Al-Jamal, K. T., Herrero, M. A., Tian, B., Ali-Boucetta, H., Hegde, V., Bianco, A., Prato, M., and Kostarelos, K. (2009). Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. *Small*, 5(10), 1176–1185.
- Podila, R. and Brown, J. M. (2013). Toxicity of engineered nanomaterials: a physicochemical perspective. *Journal of Biochemical and Molecular Toxicology*, 27(1), 50–55.

- Polat, B. E., Hart, D., Langer, R., and Blankschtein, D. (2011). Ultrasound-mediated transdermal drug delivery: mechanisms, scope and emerging trends. *Journal of Controlled Release*, 152(3), 330-348.
- Ponnamma, D., Sung, S. H., Hong, J. S., Ahn, K. H., Varughese, K. T., and Thomas, S. (2014). Influence of non-covalent functionalization of carbon nanotubes on the rheological behavior of natural rubber latex nanocomposites. *European Polymer Journal*, 53(1), 147-159.
- Porter, A. E., Gass, M., Muller, K., Skepper, J. N., Midgley, P. A., and Welland, M. (2007). Direct imaging of single-walled carbon nanotubes in cells. *Nature Nanotechnology*, 2(11), 713-717.
- Prausnitz, M. R. (2004). Microneedles for transdermal drug delivery. *Advanced Drug Delivery Reviews*, 56(5), 581-587.
- Priyanka, A., Shringi, S., and Sanjay, G. (2002). Permeability issues in nasal drug delivery. *Drug Discovery Today*, 7(18), 967-975.
- Qi, H., Ling, C., Huang, R., Qiu, X., Shangguan, L., Gao, Q., and Zhang, C. (2012). Functionalization of single-walled carbon nanotubes with protein by click chemistry as sensing platform for sensitized electrochemical immunoassay. *Electrochimica Acta*, 63, 76-82.
- Qian, F., Mathias, N., Moench, P., Chi, C., Desikan, S., Hussain, M., and Smith, R. L. (2009). Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. *International Journal of Pharmaceutics*, 366(1-2), 218-220.
- Rastogi, R., Kaushal, R., Tripathi, S. K., Sharma, A. L., Kaur, I., and Bharadwaj, L. M. (2008). Comparative study of carbon nanotube dispersion using surfactants. *Journal of Colloid and Interface Science*, 328(2), 421-428.
- Ratanajaijaroen, P., Watthanaphanit, A., Tamura, H., Tokura, S., and Rujiravanit, R. (2012). Release characteristic and stability of curcumin incorporated in β -chitin non-woven fibrous sheet using Tween 20 as an emulsifier. *European Polymer Journal*, 48(3), 512-523.
- Reilly, R. M. (2007). Carbon nanotubes: potential benefits and risks of nanotechnology in nuclear medicine. *The Journal of Nuclear Medicine*, 48(7), 1039-1042.
- Reiner, T., Parrondo, R., de las Pozas, A., Palenzuela, D., and Perez-Stable, C. (2013). Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: possible role for inhibition of deubiquitinase activity. *PLoS ONE*, 8(2), Article ID e56234.
- Ren, J., Shen, S., Wang, D., Xi, Z., Guo, L., Pang, Z., Qian, Y., Sun, X., and Jiang, X. (2012). The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multiwalled carbon nanotubes modified with angiopep-2. *Biomaterials*, 33(11), 3324-3333.

- Ren, W., Tian, G., Jian, S., Gu, Z., Zhou, L., Yan, L., Jin, S., Yin, W., and Zhao, Y. (2012). TWEEN coated NaYF₄: Yb, Er/NaYF₄ core/shell upconversion nanoparticles for bioimaging and drug delivery. *RSC Advances*, 2(18), 7037-7041.
- Renteria, S. S., Clemens, C. C., and Croyle, M. A. (2010). Development of a nasal adenovirus-based vaccine: effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices. *Vaccine*, 28(9), 2137-2148.
- Reyhani, A., Mortazavi, S. Z., Mirershadi, S., Golikand, A. N., and Moshfegh, A. Z. (2012). H₂ adsorption mechanism in Mg modified multi-walled carbon nanotubes for hydrogen storage. *International Journal of Hydrogen Energy*, 37(2), 1919-1926.
- Rojanasakul, Y., Wang, L. Y., Bhat, M., Glover, D. D., Malanga, C. J., and Ma, J. K. (1992). The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit. *Pharmaceutical Research*, 9(8), 1029-1034.
- Rydzewski, R. M. (2008). The drug discovery business to date. In Rydzewski, R.M. *Real World Drug Discovery* (pp. 1-46). United Kingdom: Elsevier Ltd.
- Sahoo, R. K., Biswas, N., Guha, A., Sahoo, N., and Kuotsu, K. (2014). Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives. *Biomed Research International*, vol. 2014, Article ID 263604, 12 pages.
- Saifullah, B., Hussein, M. Z., Hussein-Al-Ali, S. H., Arulselvan, P., and Fakurazi, S. (2013). Antituberculosis nanodelivery system with controlled-release properties based on para-amino salicylatezinc aluminum-layered double-hydroxide nanocomposites. *Drug Design, Development and Therapy*, 7, 1365-1375.
- Sakagami, M. (2006). *In vivo, in vitro* and *ex vivo* models to access pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. *Advanced Drug Delivery Reviews*, 58(9-10), 1030-1060.
- Salamat-Miller, N., Chittchang, M., and Johnston, T. P. (2005). The use of mucoadhesive polymers in buccal drug delivery. *Advanced Drug Delivery Reviews*, 57(11), 1666-1691.
- Salehi, E., Madaeni, S. S., Rajabi, L., Vatanpour, V., Derakhshan, A. A., Zinadini, S., Ghorabi, Sh., and Monfared, H. A. (2012). Novel chitosan/poly(vinyl) alcohol thin adsorptive membranes modified with amino functionalized multi-walled carbon nanotubes for Cu(II) removal from water: preparation, characterization, adsorption kinetics and thermodynamics. *Separation and Purification Technology*, 89, 309-319.
- Salib, R. J. and Howarth, P. H. (2003). Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. *Drug Safety*, 26(12), 863-893.

- Salomon, J. J. and Ehrhardt, C. (2012). Organic cation transporters in the blood-air barrier: expression and implications for pulmonary drug delivery. *Therapeutic Delivery*, 3(6), 735–747.
- Sanborn, G., Turano, S., and Ready, W. J. (2014). Oxygen plasma resurrection of triode type carbon nanotube field emission cathodes. *Diamond and Related Materials*, 43, 1–4.
- Santiago, A. J. and Factor, S. A. (2003). Levodopa. In Pahwa, R., Lyons, K., Koller, W. C. *Handbook of Parkinson's Disease* (pp. 391-415). New York: Marcel Dekker.
- Sastray, S. V., Nyshadham, J. R., and Fix, J. A. (2000). Recent technological advances in oral drug delivery – a review. *Pharmaceutical Science & Technology Today*, 3(4), 138-145.
- Sattler, K. (1995). Scanning tunneling microscopy of carbon nanotubes and nanocones. *Carbon*, 33(7), 915–920.
- Savolainen, K., Pylkkänen, L., Norppa, H., Falck, G., Lindberg, H., Tuomi, T., Vippola, M., Alenius, H., Hämeri, K., Koivisto, J., Brouwer, D., Mark, D., Bard, D., Berges, M., Jankowska, E., Posniak, M., Farmer, P., Singh, R., Krombach, F., Bihari, P., Kasper, G., and Seipenbusch, M. (2010). Nanotechnologies, engineered nanomaterials and occupational health and safety – a review. *Safety Science*, 48(8), 957–963.
- Sawant, S. Y., Somani, R. S., Bajaj, H. C., and Sharma, S. S. (2012). A dechlorination pathway for synthesis of horn shaped carbon nanotubes and its adsorption properties for CO₂, CH₄, CO and N₂. *Journal of Hazardous Materials*, 227-228, 317–326.
- Saxena, R. K., Williams, W., Mcgee, J. K., Daniels, M. J., Boykin, E., and Gilmour, M. I. (2007). Enhanced *in vitro* and *in vivo* toxicity of poly-dispersed acid-functionalized single-wall carbon nanotubes. *Nanotoxicology*, 1(4), 291-300.
- Selzer, E., Pimentel, E., Wacheck, V., Schlegel, W., Pehamberger, H., Jansen, B., and Kodym, R. (2000). Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. *Journal of Investigative Dermatology*, 114(5), 935–940.
- Sethia, S. and Squillante, E. (2004). Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. *International Journal of Pharmaceutics*, 272(1-2), 1–10.
- Setterstrom, J. A., Tice, T. R., Meyers, W. E., and Vincent, J. W. (1984). Development of encapsulated antibiotics for topical administration to wounds. *Recent Advances in Drug Delivery Systems*, 185–198.

- Shameli, K., Ahmad, M., Jazayeri, S. D., Sedaghat, S., Shabanzadeh, P., Jahangirian, H., Mahdavi, M., and Abdollahi, Y. (2012). Synthesis and characterization of polyethylene glycol mediated silver nanoparticles by the green method. *International Journal of Molecular Sciences*, 13(6), 6639-6650.
- Shao, W., Paul, A., Zhao, B., Lee, C., Rodes, L., and Prakash, S. (2013). Carbon nanotube lipid drug approach for targeted delivery of a chemotherapy drug in a human breast cancer xenograft animal model. *Biomaterials*, 34, 10109–10119.
- Sheikholeslam, M., Pritzker, M., and Chen, P. (2014). Hybrid peptide-carbon nanotube dispersions and hydrogels. *Carbon*, 71, 284–293.
- Shen, X., Yu, D., Zhu, L., Branford-White, C., White, K., and Chatterton, N. P. (2011). Electrospun diclofenac sodium loaded Eudragit L 100-55 nanofibers for colon-targeted drug delivery. *International Journal of Pharmaceutics*, 408(1-2), 200-207.
- Shi, J., Votruba, A. R., Farokhzad, O. C., and Langer, R. (2010). Nanotechnology in drug delivery and tissue engineering: from discovery to applications. *Nano Letters*, 10(9), 3223–3230.
- Shibata, N., Ohno, T., Shimokawa, T., Hu, Z., Yoshikawa, Y., Koga, K., Murakami, M., and Takada, K. (2001). Application of pressure-controlled colon delivery capsule to oral administration of glycyrrhizin in dogs. *Journal of Pharmacy and Pharmacology*, 53(4), 441-447.
- Shieh, Y. T., Liu, G. L., Wu, H. H., and Lee, C. C. (2007). Effects of polarity and pH on the solubility of acid-treated carbon nanotubes in different media. *Carbon*, 45(9), 1880–1890.
- Silambarasan, D., Surya, V. J., Vasu, V., and Iyakutti, K. (2013). Investigation of single-walled carbon nanotubes-titanium metal composite as a possible hydrogen storage medium. *International Journal of Hydrogen Energy*, 38(34), 14654–14660.
- Silva, S. M. L., Braga, C. R. C., Fook, M. V. L., Raposo, C. M. O., Carvalho, L. H., and Canedo, E. L. (2012). Application of infrared spectroscopy to analysis of chitosan/clay nanocomposites. In: Theophanides, T. (Ed.), *Infrared spectroscopy – materials science, engineering and technology* (pp. 43-62). Croatia: InTech Publisher.
- Singh, D. K., Iyer, P. K., and Giri, P. K. (2009). Optical signature of structural defects in single walled and multiwalled carbon nanotubes. *Journal of Nanoscience and Nanotechnology*, 9(9), 5396–5401.
- Singh, N., Pillay, V., and Choonara, Y. E. (2007). Advances in the treatment of Parkinson's disease. *Progress in Neurobiology*, 81(1), 29-44.

- Singh, R., Pantarotto, D., Lacerda, L., Pastorin, G., Klumpp, C., Prato, M., Bianco, A., and Kostarelos, K. (2006). Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. *Proceedings of the National Academy of Sciences of the United States of America*, 103(9), 3357–3362.
- Singh, R. P. and Agarwal, R. (2004). Prostate cancer prevention by silibinin. *Current Cancer Drug Targets*, 4(1), 1–11.
- Siriviriyannun, A., Imae, T., and Nagatani, N. (2013). Electrochemical biosensors for biocontaminant detection consisting of carbon nanotubes, platinum nanoparticles, dendrimers, and enzymes. *Analytical Biochemistry*, 443(2), 169–171.
- Smart, S. K., Cassady, A. I., Lu, G. Q., and Martin, D. J. (2006). The biocompatibility of carbon nanotubes. *Carbon*, 44, 1034-1047.
- Sohaebuddin, S. K., Thevenot, P. T., Baker, D., Eaton, J. W., and Tang, L. (2010). Nanomaterial cytotoxicity is composition, size, and cell type dependent. *Particle and Fibre Toxicology*, 7, Article 22.
- Song, W., Zheng, Z., Tang, W., and Wang, X. (2007). A facile approach to covalently functionalized carbon nanotubes with biocompatible polymer. *Polymer*, 48(13), 3658–3663.
- Sonnenbichler, J., Scalera, F., Sonnenbichler, I., and Weyhenmeyer, R. (1999). Stimulatory effects of silibinin and silicristin from the milk thistle *silybum marianum* on kidney cells. *Journal of Pharmacology and Experimental Therapeutics*, 290(3), 1375-1383.
- Sou, T., Meeusen, E. N., De Veer, M., Morton, D. A., Kaminskas, L. M., and McIntosh, M. P. (2011). New developments in dry powder pulmonary vaccine delivery. *Trends in Biotechnology*, 29(4), 191-198.
- Stachowiak, J. C., Von Muhlen, M. G., Li, T. H., Jalilian, L., Parekh, S. H., and Fletcher, D. A. (2007). Piezoelectri control of needle-free transdermal drug delivery. *Journal of Controlled Release*, 124(1-2), 88-97.
- Steckel, H. and Brandes, H. G. (2004). A novel spray-drying technique to produce low density particles for pulmonary delivery. *International Journal of Pharmaceutics*, 278(1), 187-195.
- Stern, F. (2004). Paul Ehrlich: the founder of chemotherapy. *Angewandte Chemie International Edition*, 43(33), 4254-4261.
- Stewart, B. W. and Wild, C. P. (2014). World Cancer Report 2014. France: International Agency for Research Cancer.

- Stocchi, F., Quinn, N. P., Barbato, L., Patsalos, P. N., O'Connel, M. T., Ruggieri, S., and Mardsen, C. D. (1994). Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. *Clinical Neuropharmacology*, 17(1), 38-44.
- Sudhakar, Y., Kuotsu, K., and Bandyopadhyay, A. K. (2006). Buccal bioadhesive drug delivery – a promising option for orally less efficient drugs. *Journal of Controlled Release*, 114(1), 15-40.
- Sugibayashi, K. and Morimoto, Y. (1994). Polymers for transdermal drug delivery systems. *Journal of Controlled Release*, 29(1-2), 177-185.
- Sun, N. Y., Wei, X. L., Wu, B. J., Chen, J., Lu, Y., and Wu, W. (2008). Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. *Powder Technology*, 182(1), 72–80.
- Sun, Y. F., Song, C. K., Viernstein, H., Unger, F., and Liang, Z. S. (2013). Apoptosis of human breast cancer cells induced by microencapsulated betulinic acid from sour jujube fruits through the mitochondria transduction pathway. *Food Chemistry*, 138(2-3), 1998–2007.
- Sun, Y. P., Huang, W. J., Lin, Y., Fu, K., Kitaygorodskiy, A., Riddle, L. A., Yu, Y. J., and Carroll, D. L. (2001). Soluble dendron-functionalized carbon nanotubes: preparation, characterization, and properties. *Chemistry of Materials*, 13(9), 2864-2869.
- Sung, J. C., Pulliam, B. L., and Edwards, D. A. (2007). Nanoparticles for drug delivery to the lungs. *Trends in Biotechnology*, 25(12), 563-570.
- Taghdisi, S. M., Lavaee, P., Ramezani, M., and Abnous, K. (2011). Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes. *European Journal of Pharmaceutics and Biopharmaceutics*, 77(2), 200–206.
- Tan, H. S. and Pfister, W. R. (1999). Pressure-sensitive adhesives for transdermal drug delivery systems. *Pharmaceutical Science & Technology Today*, 2(2), 60-69.
- Tan, J. M., Arulselvan, P., Fakurazi, S., Ithnin, H., and Hussein, M. Z. (2014a). A review on characterizations and biocompatibility of functionalized carbon nanotubes in drug delivery design. *Journal of Nanomaterials*, vol. 2014, Article ID 917024, 20 pages.
- Tan, J. M., Foo, J. B., Fakurazi, S., and Hussein, M. Z. (2015). Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes. *Beilstein Journal of Nanotechnology*, 6, 243-253.
- Tan, J. M., Karthivashan, G., Arulselvan, P., Fakurazi, S., and Hussein, M. Z. (2014b). *In vitro* nanodelivery of silibinin as an anticancer drug under pH response. *Journal of Drug Delivery Science and Technology*, 24(6), 579-584.

- Tan, J. M., Karthivashan, G., Arulselvan, P., Fakurazi, S., and Hussein, M. Z. (2014c). Characterization and *in vitro* sustained release of silibinin from pH responsive carbon nanotube-based drug delivery system. *Journal of Nanomaterials*, vol. 2014, Article ID 439873, 10 pages.
- Tan, J. M., Karthivashan, G., Arulselvan, P., Fakurazi, S., and Hussein, M. Z. (2014d). Sustained release and cytotoxicity evaluation of carbon nanotube-mediated drug delivery system for betulinic acid. *Journal of Nanomaterials*, vol. 2014, Article ID 862148, 11 pages.
- Tan, J. M., Karthivashan, G., Arulselvan, P., Fakurazi, S., and Hussein, M. Z. (2014e). Characterization and *in vitro* studies of the anticancer effect of oxidized carbon nanotubes functionalized with betulinic acid. *Drug Design, Development and Therapy*, 8, 2333-2343.
- Tan, S. Y. and Grimes, S. (2010). Paul Ehrlich (1854-1915): man with the magic bullet. *Singapore Medical Journal*, 51(11), 842-843.
- Tang, M., Dou, H., and Sun, K. (2006). One-step synthesis of dextranbased stable nanoparticles assisted by self-assembly. *Polymer*, 47(2), 728–734.
- Tasis, D., Tagmatarchis, N., Bianco, A., and Prato, M. (2006). Chemistry of carbon nanotubes. *Chemical Reviews*, 106(3), 1105–1136.
- Taylor, M. D. (1996). Improved passive oral drug delivery via prodrugs. *Advanced Drug Delivery Reviews*, 19(2), 131-148.
- Teng, W., Cappello, J., and Wu, X. (2011). Physical crosslinking modulates sustained drug release from recombinant silk-elastinlike protein polymer for ophthalmic applications. *Journal of Controlled Release*, 156(2), 186–194.
- Teunissen, E. A., De Raad, M., and Mastrobattista, E. (2013). Production and biomedical applications of virus-like particles derived from polyomaviruses. *Journal of Controlled Release*, 172(1), 305–321.
- Thomas, B. J. and Finnin, B. C. (2004). The transdermal revolution. *Drug Discovery Today*, 9(16), 697-703.
- Tian, Z., Shi, Y., Yin, M., Shen, H., and Jia, N. (2011). Functionalized multiwalled carbon nanotubes anticancer drug carriers: synthesis, targeting ability and antitumor activity. *Nano Biomedicine and Engineering*, 3(3), 157–162.
- Tseng, C. L., Chen, K. H., Su, W. Y., Lee, Y. H., Wu, C. C., and Lin, F. H. (2013). Cationic gelatin nanoparticles for drug delivery to the ocular surface: *in vitro* and *in vivo* evaluation. *Journal of Nanomaterials*, vol. 2013, Article ID 238351, 11 pages.
- Ugwoke, M. I., Agu, R. U., Verbeke, N., and Kinget, R. (2005). Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. *Advanced Drug Delivery Reviews*, 57(11), 1640-1665.

- Ungaro, F., Giovino, C., Coletta, C., Sorrentino, R., Miro, A., and Quaglia, F. (2010). Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. *European Journal of Pharmaceutical Sciences*, 41(1), 60-70.
- Ursini, C. L., Cavallo, D., Fresegna, A. M., Ciervo, A., Maiello, R., Casciardi, S., Tombolini, F., Buresti, G., and Iavicoli, S. (2012). Study of cytotoxic and genotoxic effects of hydroxyl-functionalized multiwalled carbon nanotubes on human pulmonary cells. *Journal of Nanomaterials*, vol. 2012, Article ID 815979, 9 pages.
- Vasudev, S. C., Chandy, T., and Sharma, C. P. (1997). Development of chitosan/polyethylene vinyl acetate co-matrix: controlled release of aspirin-heparin for preventing cardiovascular thrombosis. *Biomaterials*, 18(5), 375–381.
- Venkatesan, J., Jayakumar, R., Mohandas, A., Bhatnagar, I., and Kim, S. K. (2014). Antimicrobial activity of chitosan-carbon nanotube hydrogels. *Materials*, 7(5), 3946-3955.
- Vermehren, C., Frokjaer, S., Aurstad, T., and Hansen, J. (2006). Lung surfactant as a drug delivery system. *International Journal of Pharmaceutics*, 307(1), 89-92.
- Verschoyle, R. D., Greaves, P., Patel, K., Marsden, D. A., Brown, K., Steward, W. P., and Gescher, A. J. (2008). Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. *European Journal of Cancer*, 44(6), 898-906.
- Vuković, G., Marinković, A., Obradović, M., Radmilović, V., Čolić, M., Aleksić, R., and Uskoković, P. S. (2009). Synthesis, characterization and cytotoxicity of surface amino-functionalized water-dispersible multi-walled carbon nanotubes. *Applied Surface Science*, 255(18), 8067–8075.
- Wang, Y., Thakur, R., Fan, Q., and Michniak, B. (2005). Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. *European Journal of Pharmaceutics and Biopharmaceutics*, 60(2), 179-191.
- Wang, Y., Zhang, D., Liu, Z., Liu, G., Duan, C., Jia, L., Feng, F., Zhang, X., Shi, Y., and Zhang, Q. (2010). *In vitro* and *in vivo* evaluation of silybin nanosuspensions for oral and intravenous delivery. *Nanotechnology*, 21(15), Article ID 155104.
- Webb, B. A., Chimenti, M., Jacobson, M. P., and Barber, D. L. (2011). Dysregulated pH: a perfect storm for cancer progression. *Nature Reviews Cancer*, 11(9), 671–677.
- Wei, G., Pan, C., Reichert, J., and Jandt, K. D. (2010). Controlled assembly of protein-protected gold nanoparticles on noncovalent functionalized carbon nanotubes. *Carbon*, 48(3), 645–653.

- Wei, Y., Ye, X., Shang, X., Peng, X., Bao, Q., Liu, M., Guo, M., and Li, F. (2012). Enhanced oral bioavailability of silybin by a supersaturatable self-emulsifying drug delivery system (S-SEDDS). *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, 396, 22–28.
- Werengowska-Ciećwierz, K., Wiśniewski, M., Terzyk, A. P., Gurtowska, N., Olkowska, J., Kłoskowski, T., Drewa, T. A., Kielkowska, U., and Drużyński, S. (2014). Nanotube-mediated efficiency of cisplatin anticancer therapy. *Carbon*, 70, 46–58.
- Weyhenmeyer, R., Mascher, H., and Birkmayer, J. (1992). Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. *International Journal of Clinical Pharmacology, Therapy, and Toxicology*, 30(4), 134–138.
- Wheate, N. J., Walker, S., Craig, G. E., and Oun, R. (2010). The status of platinum anticancer drugs in the clinic and in clinical trials. *Dalton Transactions*, 39(35), 8113–8127.
- Wheeler, S. E. (2013). Understanding substituent effects in noncovalent interactions involving aromatic rings. *Accounts of Chemical Research*, 46, 1029–1038.
- Wick, P., Manser, P., Limbach, L. K., Dettlaff-Weglowska, U., Krumeich, F., Roth, S., Stark, W. J., and Bruinink, A. (2007). The degree and kind of agglomeration affect carbon nanotube cytotoxicity. *Toxicology Letters*, 168(2), 121–131.
- Wong, B. S., Yoong, S. L., Jagusiak, A., Panczyk, T., Ho, H. K., Ang, W. H., and Pastorin, G. (2013). Carbon nanotubes for delivery of small molecule drugs. *Advanced Drug Delivery Reviews*, 65(15), 1964–2015.
- Wright, M. R. (2004). The kinetic analysis of experimental data. In Wright, M. R. *An Introduction to Chemical Kinetics* (pp. 43–92). England: John Wiley & Sons.
- Wu, H., Liu, G., Zhuang, Y., Wu, D., Zhang, H., Yang, H., Hu, H., and Yang, S. (2011). The behaviour after intravenous injection in mice of multiwalled carbon nanotube/Fe₃O₄ hybrid MRI contrast agents. *Biomaterials*, 32(21), 4867–4876.
- Wu, J., Wei, W., Wang, L. Y., Su, Z. G., and Ma, G. H. (2007). A thermosensitive hydrogel based on quaternized chitosan and poly(ethyleneglycol) for nasal drug delivery system. *Biomaterials*, 28(13), 2220–2232.
- Xiong, J., Xiong, S., Guo, Z., Yang, M., Chen, J., and Fan, H. (2012). Ultrasonic dispersion of nano TiC powders aided by tween 80 addition. *Ceramic International*, 38(3), 1815–1821.
- Xu, M., Huang, Q., Chen, Q., Guo, P., and Sun, Z. (2003). Synthesis and characterization of octadecylamine grafted multi-walled carbon nanotubes. *Chemical Physics Letters*, 375(5–6), 598–604.

- Xu, X. H., Ren, G. L., Cheng, J., Liu, Q., and Li, D. G. (2006). Layer by layer self-assembly immobilization of glucose oxidase onto chitosan-graft-polyaniline polymers. *Journal of Materials Science*, 41(10), 3147-3149.
- Yan, Y., Cui, J., Pötschke, P., and Voit, B. (2010). Dispersion of pristine single-walled carbon nanotubes using pyrene-capped polystyrene and its application for preparation of polystyrene matrix composites. *Carbon*, 48(9), 2603–2612.
- Yang, F., Jin, C., Yang, D., Jiang, Y., Li, J., Di, Y., Hu, J., Wang, C., Ni, Q., and Fu, D. (2011). Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment. *European Journal of Cancer*, 47(12), 1873–1882.
- Yang, J., Liu, Y. M., and Liu, Y. Z. (2004). Advances in the pharmaceutical research on the silymarin. *Natural Product Research and Development*, 16(2), 185–187.
- Yang, K., Zhu, L. Z., and Xing, B. S. (2006). Adsorption of polycyclic aromatic hydrocarbons by carbon nanomaterials. *Environmental Science & Technology*, 40(6), 1855–1861.
- Yang, L., Chu, J. S., and Fix, J. A. (2002). Colon-specific drug delivery: new approaches and *in vitro/in vivo* evaluation. *International Journal of Pharmaceutics*, 235(1-2), 1-15.
- Yang, L. X., Huang, K. X., Li, H. B., Gong, J. X., Wang, F., Feng, Y. B., Tao, Q. F., Wu, Y. H., Li, X. K., Wu, X. M., Zeng, S., Spencer, S., Zhao, Y., and Qu, J. (2009a). Design, synthesis, and examination of neuron protective properties of alkenylated and amidated dehydro-silybin derivatives. *Journal of Medicinal Chemistry*, 52(23), 7732-7752.
- Yang, S. T., Guo, W., Lin, Y., Deng, X. Y., Wang, H. F., Sun, H. F., Liu, Y. F., Wang, X., Wang, W., Chen, M., Huang, Y. P., and Sun, Y. P. (2007). Biodistribution of pristine single-walled carbon nanotubes *in vivo*. *The Journal of Physical Chemistry C*, 111(48), 17761–17764.
- Yang, W., Chow, K. T., Lang, B., Wiederhold, N. P., Johnston, K. P., and Williams, R. O. (2010). *In vitro* characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. *European Journal of Pharmaceutical Sciences*, 39(5), 336-347.
- Yang, Y., Bajaj, N., Xu, P., Ohn, K., Tsifansky, M. D., and Yeo, Y. (2009b). Development of highly porous large PLGA microparticles for pulmonary drug delivery. *Biomaterials*, 30(10), 1947-1953.
- Yazan, L. S., Foo, J. B., Ghafar, S. A. A., Chan, K. W., Tahir, P. M., and Ismail, M. (2011). Effect of kenaf seed oil from different ways of extraction towards ovarian cancer cells. *Food and Bioproducts Processing*, 89, 328-332.
- Yeo, Y. and Park, K. (2004). Control of encapsulation efficiency and initial burst in polymeric microparticle systems. *Archives of Pharmacal Research*, 27(1), 1–12.

- Yogeeswari, P. and Sriram, D. (2005). Betulinic acid and its derivatives: a review on their biological properties. *Current Medicinal Chemistry*, 12(6), 657–666.
- Yu, J. N., Zhu, Y., Wang, L., Peng, M., Tong, S. S., Cao, X., Qiu, H., and Xu, X. M. (2010). Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles. *Acta Pharmacologica Sinica*, 31(6), 759–764.
- Yudianti, R., Onggo, H., Saito, Y., Iwata, T., and Azuma, J. (2011). Analysis of functional group sited on multi-wall carbon nanotube surface. *The Open Materials Science Journal*, 5, 242–247.
- Yuge, R., Toyama, K., Ichihashi, T., Ohkawa, T., Aoki, Y. and Manako, T. (2012). Characterization and field emission properties of multi-walled carbon nanotubes with fine crystallinity prepared by CO₂ laser ablation. *Applied Surface Science*, 258(18), 6958–6962.
- Zeng, L. and Barron, A. R. (2010). Characterization of covalently functionalized single-walled carbon nanotubes. Connexions Web Site, 2010, <http://cnx.org/content/m22299/1.4/>.
- Zeng, Q., Wen, H., Wen, Q., Chen, X., Wang, Y., Xuan, W., Liang, J., and Wan, S. (2013). Cucumber mosaic virus as drug delivery vehicle for doxorubicin. *Biomaterials*, 34(19), 4632–4642.
- Zhang, C., Sui, J., Li, J., Tang, Y., and Cai, W. (2012a). Efficient removal of heavy metal ions by thiol-functionalized superparamagnetic carbon nanotubes. *Chemical Engineering Journal*, 210, 45–52.
- Zhang, J. Q., Liu, J., Li, X. L., and Jasti, B. R. (2007). Preparation and characterization of solid lipid nanoparticles containing silibinin. *Drug Delivery*, 14(6), 381–387.
- Zhang, L., Wang, S., Zhang, M., and Sun, J. (2013). Nanocarriers for oral drug delivery. *Journal of Drug Targeting*, 21(6), 515–527.
- Zhang, L., Xue, H., Cao, Z., Keefe, A., Wang, J., and Jiang, S. (2011). Multifunctional and degradable zwitterionic nanogels for targeted delivery, enhanced MR imaging, reduction-sensitive drug release, and renal clearance. *Biomaterials*, 32(20), 4604–4608.
- Zhang, R. and Olin, H. (2012). Carbon nanomaterials as drug carriers: real time drug release investigation. *Materials Science and Engineering C*, 32(5), 1247–1252.
- Zhang, T., Tang, M., Kong, L., Li, H., Zhang, T., Zhang, S., Xue, Y., and Pu, Y. (2012b). Comparison of cytotoxic and inflammatory responses of pristine and functionalized multiwalled carbon nanotubes in RAW 264.7 mouse macrophages. *Journal of Hazardous Materials*, 219-220, 203–212.
- Zhao, X. and Liu, R. (2012). Recent progress and perspectives on the toxicity of carbon nanotubes at organism, organ, cell, and biomacromolecule levels. *Environment International*, 40(1), 244–255.

- Zheng, X., Wang, T., Jiang, H., Li, Y., Jiang, T., Zhang, J., and Wang, S. (2013). Incorporation of Carvedilol into PAMAM-functionalized MWNTs as a sustained drug delivery system for enhanced dissolution and drug-loading capacity. *Asian Journal of Pharmaceutical Sciences*, 8, 278–286.
- Zhou, O., Shimoda, H., Gao, B., Oh, S., Fleming, L., and Yue, G. (2002). Materials science of carbon nanotubes: fabrication, integration, and properties of macroscopic structures of carbon nanotubes. *Accounts of Chemical Research*, 35(12), 1045–1053.

